var title_f16_56_17280="Contents: Hepatic disease";
var content_f16_56_17280=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hepatic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hepatic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alcoholic liver disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4710\">",
"           Alcohol abuse and hematologic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/4/28744\">",
"           Alcoholic hepatitis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/698\">",
"           Alcoholic hepatitis: Natural history and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21162\">",
"           Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9496\">",
"           Hepatitis C and alcohol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/2/5160\">",
"           Liver transplantation in alcoholic liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/5/30807\">",
"           Pathogenesis of alcoholic liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22104\">",
"           Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Focal liver lesions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36888\">",
"           Approach to the patient with a focal liver lesion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/10/34986\">",
"           Clinical features and diagnosis of primary hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/58/8104\">",
"           Diagnosis and management of cystic lesions of the liver",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22791\">",
"           Focal nodular hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15352\">",
"           Hepatic adenoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/7/29816\">",
"           Hepatic hemangioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/14/37095\">",
"           Nodular regenerative hyperplasia of the liver",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29526\">",
"           Pyogenic liver abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Granulomatous liver disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40406\">",
"           Hepatic granulomas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemochromatosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/60/28617\">",
"           Clinical manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2266\">",
"           Genetics of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33748\">",
"           Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38856\">",
"           Iron overload syndromes other than hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/19/35129\">",
"           Pathophysiology and diagnosis of iron overload syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2265\">",
"           Rheumatic manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatocellular carcinoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/10/34986\">",
"           Clinical features and diagnosis of primary hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/38/25194\">",
"           Epidemiology and etiologic associations of hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/32/36362\">",
"           Liver transplantation for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/29/21978\">",
"           Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/18/36138\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/9/41114\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/6/28778\">",
"           Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25992\">",
"           Staging and prognostic factors in hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/6/14442\">",
"           Surgical management of potentially resectable hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39898\">",
"           Systemic treatment for advanced hepatocellular carcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver biopsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/50/30506\">",
"           Interpretation of liver biopsy specimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/58/29608\">",
"           Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/37/9814\">",
"           Transjugular liver biopsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver diseases in pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/38/24166\">",
"           Acute fatty liver of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26198\">",
"           Approach to liver disease occurring during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14726\">",
"           Intercurrent hepatobiliary disease during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4617\">",
"           Intrahepatic cholestasis of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/15/22777\">",
"           Pregnancy in women with pre-existing chronic liver disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2330\">",
"           Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38538\">",
"           Acute liver failure in adults: Management and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver function tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/18/34090\">",
"           Approach to the patient with abnormal liver biochemical and function tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/57/7065\">",
"           Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/28/36294\">",
"           Clinical aspects of serum bilirubin determination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/50/42790\">",
"           Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19353\">",
"           Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5���������-nucleotidase, gamma-glutamyl transpeptidase)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21494\">",
"           Liver biochemical tests that detect injury to hepatocytes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5446\">",
"           Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24022\">",
"           Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/22/22889\">",
"           Tests of the liver's capacity to transport organic anions and metabolize drugs",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27943\">",
"           Bilirubin metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13018\">",
"           Clinical manifestations, diagnosis, and natural history of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6201\">",
"           Crigler-Najjar syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/50/42790\">",
"           Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/37/13910\">",
"           Epidemiology and pathogenesis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38105\">",
"           Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18136\">",
"           Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42359\">",
"           Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16136\">",
"           Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/36/42564\">",
"           Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/34/13861\">",
"           Glycogen debrancher deficiency (glycogen storage disease III)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8314\">",
"           Inherited disorders associated with conjugated hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6836\">",
"           Liver glycogen synthase deficiency (glycogen storage disease 0)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/27/20916\">",
"           Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23882\">",
"           Natural history and management of nonalcoholic fatty liver disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40500\">",
"           Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4356\">",
"           Overview of inherited disorders of glucose and glycogen metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16073\">",
"           Pathogenesis of nonalcoholic fatty liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/41/25237\">",
"           Phosphorylase b kinase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14088\">",
"           Tests used in the diagnosis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23737\">",
"           Treatment of Wilson disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Noncirrhotic portal hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3993\">",
"           Extrahepatic portal vein obstruction (portal vein thrombosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/40/14985\">",
"           Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/46/6889\">",
"           Nutritional assessment in chronic liver disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative jaundice",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/31/9718\">",
"           Approach to the patient with postoperative jaundice",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary biliary cirrhosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41641\">",
"           Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/50/27430\">",
"           Liver transplantation in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29830\">",
"           Metabolic bone disease in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34105\">",
"           Overview of the treatment of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5737\">",
"           Pathogenesis of primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23863\">",
"           Pruritus associated with cholestasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43526\">",
"           Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Toxic diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44074\">",
"           Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/27/13754\">",
"           Drugs and the liver: Metabolism and mechanisms of injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/63/29690\">",
"           Drugs and the liver: Patterns of drug-induced liver injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25642\">",
"           Hepatotoxicity due to herbal medications and dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vanishing bile duct syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/40/21128\">",
"           Hepatic ductopenia and vanishing bile duct syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3434\">",
"           Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43701\">",
"           Congestive hepatopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/53/31575\">",
"           Etiology of the Budd-Chiari syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/49/2842\">",
"           Hepatic manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/8/18568\">",
"           Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/4/40009\">",
"           Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43013\">",
"           Pathogenesis of liver injury in circulatory failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/16/26887\">",
"           Peliosis hepatis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7081\">",
"           Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-5917906E5A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_56_17280=[""].join("\n");
var outline_f16_56_17280=null;
var title_f16_56_17281="Treatment protocols for castration-resistant prostate cancer";
var content_f16_56_17281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for castration-resistant prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17281/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/56/17281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6926555\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with prostate cancer.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with prostate cancer. Additional regimens may be added over time, particularly as treatment for prostate cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with prostate cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=see_link\">",
"       \"Chemotherapy in castrate-resistant prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119855717\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932475884\">",
"    <span class=\"h2\">",
"     Cabazitaxel and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef82196 \" href=\"UTD.htm?40/34/41517\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932475909\">",
"    <span class=\"h2\">",
"     Docetaxel and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef57477 \" href=\"UTD.htm?33/62/34797\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85678 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-C33EB2799F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17281=[""].join("\n");
var outline_f16_56_17281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6926555\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H119855717\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932475884\">",
"      Cabazitaxel and prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932475909\">",
"      Docetaxel and prednisone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/34/41517\" title=\"table 1\">",
"      Cabazitaxel and prednisone for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/62/34797\" title=\"table 2\">",
"      Docetaxel and prednisone for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17282="Hair loss in men and women (androgenetic alopecia)";
var content_f16_56_17282=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/56/17282/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17282/contributors\" id=\"au5343\">",
"       Beth G Goldstein, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17282/contributors\" id=\"au5345\">",
"       Adam O Goldstein, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/56/17282/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17282/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/56/17282/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17282/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?16/56/17282?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HAIR LOSS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The most common type of hair loss is a condition called androgenetic alopecia [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/1\">",
"      1",
"     </a>",
"     ]. This type of hair loss can affect both men and women. Other terms for androgenetic alopecia include &ldquo;male pattern balding&rdquo; and &ldquo;female pattern hair loss.&rdquo;",
"    </p>",
"    <p>",
"     For many people, losing their hair is a frustrating experience. Fortunately, treatments are available that can help to regrow hair or prevent further hair loss.",
"    </p>",
"    <p>",
"     More detailed information about androgenetic alopecia is available by subscription (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"      \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"      \"Treatment of androgenetic alopecia in men\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"      \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14344?source=see_link\">",
"      \"Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis\"",
"     </a>",
"     ). Another type of hair loss, known as alopecia areata, is also discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=see_link\">",
"      \"Patient information: Alopecia areata (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HAIR LOSS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The hair follicle is a structure that encases the lower part of the hair shaft. Each follicle contains blood vessels that nurture new hair growth. All hair follicles are present at birth; throughout the lifetime each follicle grows and sheds single hairs in a repetitive cycle.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The growth phase for a single new hair lasts two to three years.",
"      </li>",
"      <li>",
"       At the end of this time, growth ceases and the follicle enters a resting phase.",
"      </li>",
"      <li>",
"       After three to four months in the resting phase, the hair is shed and the next growth cycle begins.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     On a normal scalp, approximately 80 to 90 percent of follicles are growing at any time. Each day, about 75 follicles shed their hair while the same number enter a new growth phase.",
"    </p>",
"    <p>",
"     In men with androgenetic alopecia, hormones related to testosterone (also called androgens) cause hair follicles to have a shorter than normal growth phase, resulting in hair shafts that are abnormally short and thin. These follicles are said to be \"miniaturized.\" The reasons why some men develop androgenetic alopecia and others do not are not fully understood. It is generally accepted that genetic background strongly influences the development of androgenetic alopecia in men, but the exact way in which family history affects a man&rsquo;s chance of developing hair loss has not been determined [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Genetics also appears to play a role in the risk for androgenetic alopecia in women, although other factors (some of which remain unknown) may also be important [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/3\">",
"      3",
"     </a>",
"     ]. As an example, abnormal levels of androgens in the blood are the cause of androgenetic alopecia in a minority of women [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/3\">",
"      3",
"     </a>",
"     ]. Additional research is necessary to provide a better understanding of the role of genetics and other factors in androgenetic alopecia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HAIR LOSS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Men and women experience androgenetic alopecia with equal frequency, although it may be camouflaged better in women. In men, androgenetic alopecia is characterized by gradual hair thinning that most often affects the crown and frontal areas of the scalp (",
"     <a class=\"graphic graphic_figure graphicRef74652 \" href=\"UTD.htm?31/25/32149\">",
"      figure 1",
"     </a>",
"     ). In many men, the hairline around the temples regresses. As it moves back to the midscalp, an M-shaped hair pattern develops. The hair in areas affected by hair loss may be of various lengths and thickness, and the presence of uneven lengths and texture is a classic sign of male pattern balding.",
"    </p>",
"    <p>",
"     Women may have similar patterns of hair loss, although typically the hair loss is a little more diffuse than in men; women rarely experience loss of all their hair (",
"     <a class=\"graphic graphic_figure graphicRef74652 \" href=\"UTD.htm?31/25/32149\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HAIR LOSS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Androgenetic alopecia can usually be diagnosed by examining the scalp. In some cases, you will need blood tests to look for other causes of hair loss, like changes in hormone levels, low iron levels (anemia), or thyroid problems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PSYCHOSOCIAL IMPACT OF HAIR LOSS",
"     </span>",
"    </p>",
"    <p>",
"     The psychosocial impact of hair loss can be severe for some people, especially women, since there is little understanding or acceptance of the condition. Women may have difficulty with issues of low self-esteem or feeling unattractive.",
"    </p>",
"    <p>",
"     If you are having difficulty with the psychosocial impact of losing your hair, speak to a healthcare provider about your feelings. Providers can offer support and may recommend that a patient work with a therapist, clinical psychologist, or support group; individual and group therapy can help patients adjust and cope with hair loss, and may also provide tips on cosmetic coverings.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HAIR LOSS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Two medications, minoxidil and finasteride, are available to treat male pattern balding in men. Women can be treated with minoxidil or a medication called spironolactone. Occasionally, finasteride is used in women who do not respond to other therapies, but it is not clear whether it is effective [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/4\">",
"      4",
"     </a>",
"     ]. Surgical options may also be considered in some cases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Minoxidil (Rogaine&reg;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minoxidil promotes hair growth by lengthening the growth phase of hair follicles and causing more follicles to produce hair. The hairs that are produced tend to be larger and thicker. Minoxidil is available in a 2 and 5 percent liquid or 5 percent foam. The 5 percent solution is more effective in men and is probably more effective in women [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/5\">",
"      5",
"     </a>",
"     ]. It can be purchased without a prescription.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      How to apply",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minoxidil is a scalp treatment, not a hair treatment. One milliliter of the liquid or foam should be applied to the affected areas of the scalp using a dropper or pump spray device. The solution should be lightly spread over the affected area with a finger, and does not need to be massaged into the scalp. People using minoxidil must have a normal, healthy scalp since cuts or openings can allow the solution to be absorbed into the bloodstream.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Results",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minoxidil must be used for at least six months to determine if it is effective. When it is effective, you usually begin to shed less hair within two months after the start of treatment, and by four to eight months hair begins to grow. The effects of minoxidil usually stabilize after 12 to 18 months of use.",
"    </p>",
"    <p>",
"     Treatment with minoxidil must be continued indefinitely. If it is discontinued, any hair that has been maintained or regrown as a result of the medication will be lost.",
"    </p>",
"    <p>",
"     Not all people benefit from minoxidil. The best results are seen when baldness has been present for less than five years, when it affects the crown (top) of the head, and when the area of hair loss is less than 10 centimeters in diameter. Studies have shown that 30 to 40 percent of men and women with crown hair loss experience cosmetically significant results with minoxidil [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/6,7\">",
"      6,7",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minoxidil causes few side effects. Occasionally, the skin may become irritated. Body-wide side effects are possible if minoxidil is absorbed through cracks or cuts in the scalp. People with a history of heart disease, in particular, should watch for systemic side effects, such as an increased heart rate, swelling in the hands or feet, or weight gain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Finasteride (Propecia&reg;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Finasteride is a pill that decreases the production of one of the hormones associated with androgenetic alopecia, resulting in an increased amount of hair covering more of the scalp [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/8\">",
"      8",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Men can take finasteride by mouth at a dose of 1 milligram (mg) per day. Higher doses of finasteride (such as those used to treat some prostate conditions) can cause side effects including erectile dysfunction and decreased sex drive. However, such side effects are rarely seen with the 1 mg dose used to treat hair loss.",
"    </p>",
"    <p>",
"     Finasteride is not safe for use in women who could become pregnant because of concerns regarding the development of abnormal genitalia in the male fetus; these women should not even touch finasteride pills. Finasteride has not been proven to help regrow hair in most women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Spironolactone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Spironolactone also decreases the production of hormones that contribute to androgenetic alopecia. Women with androgenetic alopecia who do not respond to minoxidil may benefit from the addition of spironolactone. Like finasteride, spironolactone should not be taken during pregnancy. Women who are able to get pregnant must use reliable contraception while taking this drug.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;For some patients, surgical treatment of hair loss may be an option. Surgical options include hair transplantation, in which healthy follicles from other parts of the scalp are transplanted to areas affected by baldness. Scalp reduction is another procedure sometimes performed. In scalp reduction, bald patches of the scalp are removed and the remaining skin is sewn together.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287481620\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15858913\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/18/7458?source=see_link\">",
"      Patient information: Hair loss in men and women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15858930\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=see_link\">",
"      Patient information: Alopecia areata (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14344?source=see_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link\">",
"      Nonscarring hair loss",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/hairdiseasesandhairloss.html\">",
"      www.nlm.nih.gov/medlineplus/hairdiseasesandhairloss.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Hair Loss Council",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ahlc.org/\">",
"      www.ahlc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aad.org/public/publications/pamphlets/common_hairloss.html\">",
"      www.aad.org/public/publications/pamphlets/common_hairloss.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?16/56/17282/abstract/1,5-10\">",
"      1,5-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?16/56/17282?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Olsen EA. Androgenetic alopecia. In: Disorders of hair growth: Diagnosis and treatment, Olsen EA (Ed), McGraw-Hill, New York 1994. p.257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/2\">",
"      Stough D, Stenn K, Haber R, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc 2005; 80:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/3\">",
"      Camacho-Mart&iacute;nez FM. Hair loss in women. Semin Cutan Med Surg 2009; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/4\">",
"      Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother 2010; 44:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/5\">",
"      Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/6\">",
"      Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/7\">",
"      DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol 1994; 130:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/8\">",
"      Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/9\">",
"      Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17282/abstract/10\">",
"      Iorizzo M, Vincenzi C, Voudouris S, et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142:298.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f16_56_17282=[""].join("\n");
var outline_f16_56_17282=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HAIR LOSS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HAIR LOSS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HAIR LOSS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HAIR LOSS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PSYCHOSOCIAL IMPACT OF HAIR LOSS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HAIR LOSS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32149\" title=\"figure 1\">",
"           Male and female pattern hair loss PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17283="Nodular basal cell carcinoma";
var content_f16_56_17283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17283=[""].join("\n");
var outline_f16_56_17283=null;
var title_f16_56_17284="Ceftibuten: Patient drug information";
var content_f16_56_17284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ceftibuten: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8101?source=see_link\">",
"     see \"Ceftibuten: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=see_link\">",
"     see \"Ceftibuten: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cedax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ceftibuten or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take capsule with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (suspension) on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11895 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17284=[""].join("\n");
var outline_f16_56_17284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148028\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024874\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024873\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024878\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024879\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024881\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024876\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024877\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024882\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024883\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8101?source=related_link\">",
"      Ceftibuten: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/44/24260?source=related_link\">",
"      Ceftibuten: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17285="Penicilloyl-polylysine: Drug information";
var content_f16_56_17285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicilloyl-polylysine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/56/22404?source=see_link\">",
"    see \"Penicilloyl-polylysine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pre-Pen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic aid for detection of penicillin allergy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Benzylpenicilloyl polylysine should always be applied first via the puncture technique.",
"     <b>",
"      Do not administer intradermally to patients who have a positive reaction to the puncture test.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Puncture test:",
"     </i>",
"     Apply a small drop of the skin test solution using a 22- to 28-gauge needle and make a single shallow puncture of the epidermis through the drop of solution. A positive reaction consists of a pale wheal surrounding the puncture site which develops within 10 minutes and ranges from 5-15 mm or more in diameter (wheal may be surrounded by erythema and variable degrees of itching). If a positive response is evident, the solution should be wiped off immediately.  If the puncture test is negative or equivocal (&lt;5 mm wheal, with little or no erythema and no itching) 15 minutes following the puncture test, an intradermal test may be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Intradermal test:",
"     </i>",
"     Using a 0.5-1 mL tuberculin syringe with a",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     to",
"     <sup>",
"      5",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     inch, 26- to 30-gauge short bevel needle, inject a volume of skin test solution sufficient to raise a small intradermal bleb ~3 mm in diameter intradermally, in duplicate at least 2 cm apart. A control of 0.9% sodium chloride or allergen-diluting solution should be injected at least 5 cm from the antigen test site. Most skin responses to the intradermal test will develop within 5-15 minutes. A response to the skin test is read at 20 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Interpretation of intradermal test:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (-) Negative: No increase in size of original bleb or no greater reaction compared to the control site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (&plusmn;) Ambiguous: Wheal only slightly larger than original bleb with or without erythematous flare and slightly larger than control site; OR discordance between duplicate test sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (+) Positive: Itching and marked increase in size of original bleb to &ge;5 mm. Wheal may exhibit pseudopods and be &gt;20 mm in diameter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Control site should be reactionless. If wheal &gt;2-3 mm develops at control site, repeat the test. If same reaction occurs, consultation is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/56/22404?source=see_link\">",
"      see \"Penicilloyl-polylysine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pre-Pen&reg;: 6 x 10",
"     <sup>",
"      -5",
"     </sup>",
"     M (0.25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Puncture test: Administer initially by puncture technique on the inner volar aspect of the forearm, followed  by an intradermal injection only in patients with a negative reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intradermal: Do",
"     <b>",
"      not",
"     </b>",
"     administer intradermally to patients with a positive reaction (wheal of 5-15 mm or more in diameter). Administer the intradermal test on the upper, outer arm, below the deltoid muscle in the event a severe hypersensitivity reaction occurs and a tourniquet needs to be applied. During the skin test, immediate treatment with epinephrine should also be available.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in assessing the risk of administering penicillin (penicillin G or benzylpenicillin) in patients suspected of clinical penicillin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10826065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in assessment of hypersensitivity to other beta-lactam antibiotics (penicillins and cephalosporins) to determine the safety of penicillin administration in patients with a history of reaction to cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, pruritus, erythema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation (intense; at skin test site), wheal (locally)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Systemic allergic reactions (including anaphylaxis; rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic or marked local reaction to a previous administration of benzylpenicilloyl polylysine skin test; patients with a known severe hypersensitivity to penicillin should not be tested",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Rare systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should only be performed by skilled medical personnel under direct supervision of a physician, and testing should be performed only in an appropriate healthcare setting prepared for the immediate treatment with epinephrine. To decrease the risk of a systemic allergic reaction, the manufacturer recommends puncture skin testing prior to intradermal testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe penicillin allergy: Patients with a reliable history of a severe life-threatening penicillin allergy, including Stevens-Johnson syndrome or TEN, should",
"     <b>",
"      NOT",
"     </b>",
"     receive penicillin skin testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Histamine H",
"     <sub>",
"      1",
"     </sub>",
"     antagonists: Responses to skin testing may be attenuated by concurrent administration of antihistamines. Consider delaying testing until these medications can be withheld to allow time for their effects dissipate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accuracy: According to the manufacturer, a negative skin test is associated with an incidence of immediate allergic reactions of &lt;5% after penicillin administration and a positive skin test may indicate &gt;50% incidence of allergic reaction occurring after penicillin administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Adequate penicillin skin testing should ideally involve reagents of both the major antigenic determinant (penicilloyl-polylysine) and minor determinants (penicilloate or penilloate). Benzylpenicilloyl polylysine alone does not identify those patients who react to a minor antigenic determinant. The minor determinant mixture (MDM) is not commercially available in the U.S.; however, diluted penicillin G (concentration: 10,000 units/mL) has been used as a minor determinant for skin testing purposes (Bernstein, 2008). Penicillin skin testing does not predict the occurrence of late reactions (eg, type II, III, IV or idiopathic reactions).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin; EPINEPHrine (Nasal); Isometheptene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Naphazoline (Nasal); Naphazoline (Ophthalmic); Oxymetazoline (Nasal); Phenylephrine (Nasal); Phenylephrine (Ophthalmic); Phenylephrine (Topical); Propylhexedrine; Xylometazoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with benzylpenicilloyl polylysine. The Centers for Disease Control and Prevention (CDC) states that penicillin skin testing may be useful in assessing suspected penicillin hypersensitivity in pregnant women diagnosed with syphilis (of any stage) due to a lack of proven alternatives to the use of penicillin in this population (CDC, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pre-Pen Intradermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mL (0.25 mL): $80.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzylpenicilloyl polylysine, a conjugate of the benzylpenicilloyl structural group (hapten) and the poly-l-lysine carrier (protein), is an antigen which reacts with  benzylpenicilloyl IgE antibodies to elicit the release of chemical mediators, thereby producing type I (immediate or accelerated) urticarial reactions in patients hypersensitive to penicillins.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Allergy, Asthma, and Immunology (AAAAI) Position Statement: &ldquo;Cephalosporin Administration to Patients With a History of Penicillin Allergy.&rdquo; Available at file://www.aaaai.org/members/academy_statements/position_statements/cephalosporin_paper.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein IL, Li JT, Bernstein DI, et al, &ldquo;Allergy Diagnostic Testing: An Updated Practice Parameter,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2008, 100(3 Suppl 3):1-148.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/56/17285/abstract-text/18431959/pubmed\" id=\"18431959\" target=\"_blank\">",
"        18431959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DYM, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 55(RR-11):1-94. Available at",
"      <a href=\"file://www.cdc.gov/std/treatment/2006/rr5511.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/std/treatment/2006/rr5511.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macy E, Mangat R, and Burchette RJ, &ldquo;Penicillin Skin Testing in Advance of Need: Multiyear Follow-up in 568 Test Result-Negative Subjects Exposed to Oral Penicillins,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2003, 111(5):1111-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/56/17285/abstract-text/12743578/pubmed\" id=\"12743578\" target=\"_blank\">",
"        12743578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salkind AR, Cuddy PG, and Foxworth JW, &ldquo;The Rational Clinical Examination. Is This Patient Allergic to Penicillin? An Evidence-Based Analysis of the Likelihood of Penicillin Allergy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2498-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/56/17285/abstract-text/11368703/pubmed\" id=\"11368703\" target=\"_blank\">",
"        11368703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wendel GD Jr, Stark BJ, Jamison RB, et al, &ldquo;Penicillin Allergy and Desensitization in Serious Infections During Pregnancy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 312(19):1229-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/56/17285/abstract-text/3921835/pubmed\" id=\"3921835\" target=\"_blank\">",
"        3921835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15949 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-BD8FC545DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17285=[""].join("\n");
var outline_f16_56_17285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140317\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140310\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140314\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140311\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682280\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682281\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140287\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140302\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140300\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826065\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140315\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140304\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140291\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298849\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140295\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140297\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323015\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140290\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/56/22404?source=related_link\">",
"      Penicilloyl-polylysine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17286="Pancreaticojejunostomy reconstruction";
var content_f16_56_17286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Pancreaticojejunostomy reconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 654px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Howard A. Reber, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17286=[""].join("\n");
var outline_f16_56_17286=null;
var title_f16_56_17287="Overview of infertility";
var content_f16_56_17287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Wendy Kuohung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17287/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/56/17287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is a common condition with important psychologic, economic, demographic, and medical implications. Demand for infertility services has grown substantially even though the prevalence of infertility has been stable. This phenomenon may be due to entry of the \"baby boom\" generation into the reproductive age group during a period of highly publicized technologic advances, and unparalleled publicity given to fertility issues in the lay press.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of infertility issues. More detailed discussions of both male and female infertility are found elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"       \"Causes of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"       \"Evaluation of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"       \"Overview of treatment of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"       \"Evaluation of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is a unique medical condition because it involves a couple, rather than a single individual. It is defined as failure of a couple to conceive after 12 months of regular intercourse without use of contraception in women less than 35 years of age; and after six months of regular intercourse without use of contraception in women 35 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/1\">",
"     1",
"    </a>",
"    ]. Some clinicians use the term subfertility to describe this failure to conceive unless the couple has been proven to be sterile.",
"   </p>",
"   <p>",
"    Fecundability, the probability of achieving a pregnancy in one menstrual cycle, is a more accurate descriptor because it recognizes varying degrees of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of fecundability has proven useful for establishing normal parameters in studies of fertility potential:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study examined the number of months to conception in 5574 normal women who had unprotected intercourse and who became pregnant between 1946 and 1956 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/2\">",
"       2",
"      </a>",
"      ]. Eighty-five percent of the women conceived within 12 months. Fecundability was 0.25 in the first three months of observation, and then decreased to 0.15 during the next nine months of observation.",
"     </li>",
"     <li>",
"      Another study of 200 healthy couples who desired pregnancy also noted that fecundability declined from 0.25 in the first three months to 0.11 in the next nine months of observation (",
"      <a class=\"graphic graphic_figure graphicRef80057 \" href=\"UTD.htm?11/24/11661\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/3\">",
"       3",
"      </a>",
"      ]. Eighty-two percent of the couples conceived within 12 months.",
"     </li>",
"     <li>",
"      A study conducted in China reported that 518 newly married textile workers aged 20 to 34 years who intended to conceive did so at a rate of about 50 percent within two cycles and 88 percent within six months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/4\">",
"       4",
"      </a>",
"      ]. Monthly fecundity ranged from 0.30 to 0.35.",
"     </li>",
"     <li>",
"      A prospective European study investigated 346 users of natural family planning methods who were trying to achieve conception [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/5\">",
"       5",
"      </a>",
"      ]. The estimated cumulative probabilities of conception for the total group at 1, 3, 6, and 12 months were 38, 68, 81, and 92 percent, respectively. The authors postulated that after six months, 50 percent of the remaining couples were subfertile or infertile.",
"     </li>",
"     <li>",
"      A study of a random sample of 867 women from the general population having unprotected intercourse with a male partner reported pregnancy rates within 6, 12, and 24 months of 54, 76, and 89 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these studies demonstrate that the large majority (80 to 90 percent) of apparently normal couples will conceive within the first year of attempted conception, they also show that the fecundability of the cohort decreases over time and with increasing age of the female partner. Thus, the possibility of infertility may be suspected after only six months of unprotected intercourse without conception. Patients who have not achieved pregnancy after 12 months have even lower fecundability. Five to 15 percent of apparently normal couples will conceive in the second 12 months of attempted conception so that after 24 months of trying to become pregnant, 95 percent of couples will have conceived.",
"   </p>",
"   <p>",
"    Several authorities have proposed a system of prognostic grading in conjunction with statements describing the couple's fertility history and diagnosis in order to reduce confusing terminology and to facilitate an appropriate treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/7\">",
"     7",
"    </a>",
"    ]. This system has not yet been widely accepted. In general, women who are under age 30, who have a less than two-year history of infertility, who have had a previous pregnancy, and who do not have tubal disease, anovulation, partners with male factor infertility, or endometriosis, have the best prognosis for treatment-independent conception [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVALENCE OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Survey of Family Growth interviewed 15,303 married women aged 15 to 44 to estimate the prevalence of infertility in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/9\">",
"     9",
"    </a>",
"    ]. Married women were considered infertile if they reported they had not conceived over the past 12 months and were sexually active and not using contraception or surgically sterilized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/9\">",
"     9",
"    </a>",
"    ]. From 1982 to 2002, the percentage of married women meeting these criteria for infertility fell from 8.5 to 7.4 percent. This figure is lower than the incidence of infertility estimated from prospective studies in the United States, which ranges from 12 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the estimated percent of married women with impaired fecundity increased from 11 percent in 1982 to 15 percent in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/11\">",
"     11",
"    </a>",
"    ]. Impaired fecundity was defined as a 36-month interval of unprotected sexual activity without conception or the woman's perception that it was physically impossible or difficult for her to conceive or her husband to father a child (does not include surgically sterile individuals).",
"   </p>",
"   <p>",
"    The reasons for these discordant trends cannot be fully explained. However, it is clear that many women seek medical advice and intervention to help them become pregnant. The National Survey of Family Growth reported that 1.2 million women (2 percent of reproductive aged women) had one or more visits with a health care provider for this indication in 2002 and 10 percent had received infertility services at some time in their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, the prevalence of infertility is highest in Eastern Europe, North",
"    <span class=\"nowrap\">",
"     Africa/Middle",
"    </span>",
"    East, Oceania, and Sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/12\">",
"     12",
"    </a>",
"    ]. Worldwide, in 2010, 1.9 percent of women aged 20 to 44 years who wanted to have children were unable to have their first live birth and 10.5 percent of women with a previous live birth were unable to have an additional live birth. In this study, infertility was defined as &ldquo;the absence of a live birth for women who desire a child and have been in a union for at least five years, during which they have not used any contraceptives&rdquo;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether fecundity varies among racial and ethnic groups when adjusted for confounders. T",
"   </p>",
"   <p>",
"    The National Survey of Family Growth found that married black women had about twice the odds of infertility as married white women, after adjustment for education, income, and self-reported history of pelvic inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/9\">",
"     9",
"    </a>",
"    ]. Others have shown that this disparity cannot be explained by differences in common risk factors for infertility, such as smoking, obesity, fibroids, or ovarian volume [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This report also noted that the proportion of US Hispanic women reporting infertility has remained stable and white women have experienced a decline. There are no data on US Asian women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAUSES OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) task force on Diagnosis and Treatment of Infertility performed a study of 8500 infertile couples and utilized standard diagnostic criteria to determine the medical conditions contributing to infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/14\">",
"     14",
"    </a>",
"    ]. In developed countries, female factor infertility was reported in 37 percent of infertile couples, male factor infertility in 8 percent, and both male and female factor infertility in 35 percent. Five percent of couples had unexplained infertility and 15 percent became pregnant during the study. This study illustrates that infertility should not be assumed to result primarily from disorders in the female partner.",
"   </p>",
"   <p>",
"    Some causes of infertility are easily identifiable, such as azoospermia (no sperm cells in the ejaculate), longstanding amenorrhea, or bilateral tubal obstruction. However, the situation is less clear in most couples: the sperm may be reduced in number, but are not absent; there may be oligomenorrhea with some ovulatory cycles; the woman may have partial tubal obstruction; or a menstrual history may suggest intermittent ovulation. It is often difficult to weigh or prioritize these findings when counseling infertile couples or planning treatment programs.",
"   </p>",
"   <p>",
"    Adding to the complexity of the situation, there are few data regarding the predictive validity of these tests despite their widespread use. Thus, short of the absolute infertility factors mentioned (eg, azoospermia or bilateral tubal obstruction), an abnormal test result cannot be said to be the cause of infertility in a particular couple.",
"   </p>",
"   <p>",
"    The uncertain causal relationship between an abnormality on infertility testing and the actual cause of infertility makes it difficult to estimate the relative frequency of the causes of infertility. Nevertheless, it is instructive to estimate the frequency with which various factors are found in association with infertility as a rough proxy for their relative importance. One population-based study reported the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male factor (hypogonadism, post-testicular defects, seminiferous tubule dysfunction) &mdash; 26 percent",
"     </li>",
"     <li>",
"      Ovulatory dysfunction &mdash; 21 percent",
"     </li>",
"     <li>",
"      Tubal damage &mdash; 14 percent",
"     </li>",
"     <li>",
"      Endometriosis &mdash; 6 percent",
"     </li>",
"     <li>",
"      Coital problems &mdash; 6 percent",
"     </li>",
"     <li>",
"      Cervical factor &mdash; 3 percent",
"     </li>",
"     <li>",
"      Unexplained &mdash; 28 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of these factors in infertility is similar whether infertility is primary or secondary, and has not changed significantly over the past 25 years in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These causes are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"       \"Causes of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WHO SHOULD PERFORM THE INFERTILITY EVALUATION?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility evaluations should be directed by fertility specialists or physicians with experience in the evaluation and treatment of infertility, where available. In many cases, it is appropriate for primary care physicians to initiate portions of the infertility evaluation. In general, obstetricians-gynecologists should be able to perform the basics of the fertility work-up. In observational studies, however, providers with expertise in diagnosis and treatment of infertility tended to provide more cost-effective care than less experienced primary care providers, and were generally more able to fulfill the emotional, informational, and diagnostic needs of their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. Although a less experienced provider may initiate the infertility evaluation, couples with abnormal test results should be referred to a specialist.",
"   </p>",
"   <p>",
"    Specific guidelines for practices offering assisted reproductive technologies have been developed by the American Society for Reproductive Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TIMING OF INFERTILITY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general consensus among infertility experts is that infertility evaluation should be undertaken for couples who have not been able to conceive after 12 months of unprotected and frequent intercourse, but earlier evaluation should be undertaken based on medical history and physical findings, and in women over 35 years of age (",
"    <a class=\"graphic graphic_table graphicRef70415 \" href=\"UTD.htm?28/62/29675\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Some authorities have proposed initiating an infertility work-up after six months of fertility-oriented intercourse without conception since prospective cohort studies have shown that a significant decline in fecundity occurs by this time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/4,5,26\">",
"     4,5,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of initial evaluation of infertility depends upon the age of the female partner, as well as the couple's historical risk factors (",
"    <a class=\"graphic graphic_table graphicRef50278 \" href=\"UTD.htm?19/63/20476\">",
"     table 2",
"    </a>",
"    ). Women experience a decline in fecundity as the ovary ages, especially after age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/27\">",
"     27",
"    </a>",
"    ]. Significantly delaying the evaluation and treatment of an infertile woman in her mid-thirties may diminish the success rate once therapy is initiated (",
"    <a class=\"graphic graphic_figure graphicRef82068 \" href=\"UTD.htm?33/54/34671\">",
"     figure 2",
"    </a>",
"    ). For these reasons, in women between 35 and 40 years of age, we initiate the infertility evaluation after six months of frequent unprotected intercourse without conception and we initiate the evaluation after less than six months in women over 40 years of age.",
"   </p>",
"   <p>",
"    Evaluation is also initiated promptly if the female partner has a history of risk factors for premature ovarian failure (previous extensive ovarian surgery, exposure to cytotoxic drugs or pelvic radiation therapy, autoimmune disease, smoking, strong family history of early",
"    <span class=\"nowrap\">",
"     menopause/premature",
"    </span>",
"    ovarian failure), advanced stage endometriosis, or known or suspected",
"    <span class=\"nowrap\">",
"     uterine/tubal",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/28\">",
"     28",
"    </a>",
"    ]. Male factors can also be indications for initiating early evaluation of the male partner. These factors include a history of testicular trauma requiring treatment, adult mumps, impotence or other sexual dysfunction, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation, or a history of subfertility with another partner.",
"   </p>",
"   <p>",
"    For younger couples who present with fewer than 12 months of attempted conception, we suggest focusing the initial intervention on teaching timed intercourse with the aid of a urinary ovulation predictor kit, and advising that they wait at least 12 months before initiating the infertility evaluation. This recommendation may be modified to fit the specific circumstances of the couple.",
"   </p>",
"   <p>",
"    In addition, we recommend changes in lifestyle factors that may improve fertility, including achieving an ideal body mass index, cessation of smoking, and limiting exposure to caffeine and alcohol. As discussed above, evaluation is initiated sooner if the female partner has a history of",
"    <span class=\"nowrap\">",
"     oligomenorrhea/amenorrhea,",
"    </span>",
"    chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation, or endometriosis, known or suspected tubal disease, or if male risk factors are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INFERTILITY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition, evaluation, and treatment of infertility are stressful for most couples. The clinician should not ignore the couple's emotional state, which may include depression, anger, anxiety, and marital discord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/52/22343?source=see_link\">",
"     \"Psychological stress and infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to remember that the couple may have multiple factors contributing to their infertility; therefore, a complete initial diagnostic evaluation, including a complete history and physical examination, should be performed. This will detect the most common causes of infertility, if present. Evaluation of both partners is performed concurrently [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following tests are useful in most couples with infertility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semen analysis to assess male factors",
"     </li>",
"     <li>",
"      Menstrual history, assessment of LH surge in urine prior to ovulation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      luteal phase progesterone level to assess ovulatory function",
"     </li>",
"     <li>",
"      Hysterosalpingography to assess tubal patency and the uterine cavity.",
"     </li>",
"     <li>",
"      Day 3 serum FSH and estradiol levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In select couples, the following additional tests may be warranted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic ultrasound to assess for uterine myomas and ovarian cysts",
"     </li>",
"     <li>",
"      Laparoscopy to identify endometriosis or other pelvic pathology",
"     </li>",
"     <li>",
"      Assessment of ovarian reserve in women &gt;35 years of age; this may involve a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      challenge test, ultrasound for early follicular antral follicle count, day 3 serum inhibin B level, or antim&uuml;llerian hormone measurement.",
"     </li>",
"     <li>",
"      Assessment of thyroid function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed description of the approach to evaluation of the male and female partners can be found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"       \"Evaluation of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"       \"Evaluation of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the cause of infertility is identified, therapy aimed at correcting reversible etiologies and overcoming irreversible factors can be implemented. The couple is also counseled on lifestyle modifications to improve fertility, such as smoking cessation, reducing excessive caffeine and alcohol consumption, and appropriate timing and frequency of coitus (every one to two days around the expected time of ovulation or according to an ovulation predictor kit). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic interventions for treatment of male and female infertility may involve drug therapy, surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    procedures such as intrauterine insemination or in vitro fertilization. Further research on causes of infertility and therapeutic modalities is needed to improve the overall success of infertility treatment. Reducing the cost of therapy, the risk of multiple gestation, and complications such as ovarian hyperstimulation will improve patient acceptance of, and the safety of, infertility therapy.",
"   </p>",
"   <p>",
"    The only absolute contraindications to infertility therapy are contraindication to pregnancy and contraindication to use of the drugs or surgery used to enhance fertility. The ethics of restricting infertility therapy for other reasons, such as parental child-rearing ability, severe obesity, life-style issues (tobacco smoking, alcohol consumption), are controversial and beyond the scope of this review [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The parent's marital status, sexual orientation, and HIV status should not be used to deny infertility treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who use infertility therapies (IVF or non-IVF) appear to have a small but statistically significant increase in risk of some pregnancy complications, such as preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17287/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Compared to the general population, an increased risk of adverse pregnancy outcomes has also been observed among untreated subfertile women who conceived naturally. The relationship between various the causes of infertility, types of infertility treatment, and pregnancy outcomes requires further study to determine the specific risks and the mechanisms involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approaches to treatment of the male and female partners are described in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"       \"Overview of treatment of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"       \"Unexplained infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"       \"Patient information: Infertility in couples (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"       \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infertility is classically defined as the failure of a couple to conceive after 12 months of frequent intercourse without use of contraception in women under age 35, and after six months in women over age 35. Fecundability is the probability of achieving a pregnancy in one menstrual cycle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eighty to 90 percent of couples will conceive within 12 months of attempting pregnancy. Fecundability progressively decreases over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infertility can be due to male factors, female factors, or factors contributed by both partners. Identifiable male factors include hypogonadism, post-testicular defects, and seminiferous tubule dysfunction. Diagnosable female factors include ovulatory dysfunction, tubal damage, endometriosis, and cervical factor. In some cases, infertility is due to coital problems or is unexplained. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Causes of infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general consensus among infertility experts is that infertility evaluation should be undertaken for couples who have not been able to conceive after 12 months of unprotected and frequent intercourse, but earlier evaluation can be justified based on medical history and physical findings, and in women over 35 years of age. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Timing of infertility evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Components of the basic infertility evaluation include history and physical examination, semen analysis, menstrual history, laboratory tests, and assessment of the fallopian tubes and uterus using hysterosalpingography, hysteroscopy, ultrasonography,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laparoscopy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Infertility evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the cause of infertility is identified, therapy aimed at correcting reversible etiologies and overcoming irreversible factors can be implemented. Therapeutic interventions for treatment of male and female infertility may involve drug therapy, surgery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      procedures such as intrauterine insemination or in vitro fertilization. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/1\">",
"      Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 90:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/2\">",
"      GUTTMACHER AF. Factors affecting normal expectancy of conception. J Am Med Assoc 1956; 161:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/3\">",
"      Zinaman MJ, Clegg ED, Brown CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/4\">",
"      Wang X, Chen C, Wang L, et al. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/5\">",
"      Gnoth C, Godehardt D, Godehardt E, et al. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 2003; 18:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/6\">",
"      Slama R, Hansen OK, Ducot B, et al. Estimation of the frequency of involuntary infertility on a nation-wide basis. Hum Reprod 2012; 27:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/7\">",
"      Habbema JD, Collins J, Leridon H, et al. Towards less confusing terminology in reproductive medicine: a proposal. Fertil Steril 2004; 82:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/8\">",
"      Van Voorhis BJ. Outcomes from assisted reproductive technology. Obstet Gynecol 2006; 107:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/9\">",
"      Stephen EH, Chandra A. Declining estimates of infertility in the United States: 1982-2002. Fertil Steril 2006; 86:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/10\">",
"      Thoma ME, McLain AC, Louis JF, et al. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertil Steril 2013; 99:1324.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/nchs/products/pubs/pubd/series/sr23/pre-1/pre-1.htm. (Accessed October 5, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/12\">",
"      Mascarenhas MN, Flaxman SR, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 2012; 9:e1001356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/13\">",
"      Wellons MF, Lewis CE, Schwartz SM, et al. Racial differences in self-reported infertility and risk factors for infertility in a cohort of black and white women: the CARDIA Women's Study. Fertil Steril 2008; 90:1640.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Technical Report Series. Recent Advances in Medically Assisted Conception Number 820, 1992, pp 1-111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/15\">",
"      Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985; 291:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/16\">",
"      Bhattacharya S, Porter M, Amalraj E, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod 2009; 24:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/17\">",
"      Kerr J, Brown C, Balen AH. The experiences of couples who have had infertility treatment in the United Kingdom: results of a survey performed in 1997. Hum Reprod 1999; 14:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/18\">",
"      VanderLaan B, Karande V, Krohm C, et al. Cost considerations with infertility therapy: outcome and cost comparison between health maintenance organization and preferred provider organization care based on physician and facility cost. Hum Reprod 1998; 13:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/19\">",
"      Halman LJ, Abbey A, Andrews FM. Why are couples satisfied with infertility treatment? Fertil Steril 1993; 59:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/20\">",
"      Ceballo R, Abbey A, Schooler D. Perceptions of women's infertility: what do physicians see? Fertil Steril 2010; 93:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/21\">",
"      Wilkes S, Hall N, Crosland A, et al. General practitioners' perceptions and attitudes to infertility management in primary care: focus group study. J Eval Clin Pract 2007; 13:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/22\">",
"      Wilkes S, Hall N, Crosland A, et al. Patient experience of infertility management in primary care: an in-depth interview study. Fam Pract 2009; 26:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/23\">",
"      Practice Committee of Society for Assisted Reproductive Technology, Practice Committee of American Society for Reproductive Medicine. Revised minimum standards for practices offering assisted reproductive technologies. Fertil Steril 2008; 90:S165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/24\">",
"      Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 89:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/25\">",
"      Committee on Gynecologic Practice of American College of Obstetricians and Gynecologists, Practice Committee of American Society for Reproductive Medicine. Age-related fertility decline: a committee opinion. Fertil Steril 2008; 90:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/26\">",
"      Brosens I, Gordts S, Valkenburg M, et al. Investigation of the infertile couple: when is the appropriate time to explore female infertility? Hum Reprod 2004; 19:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/27\">",
"      Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med 1982; 306:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/28\">",
"      Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2012; 98:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/29\">",
"      ESHRE Task Force on Ethics and Law, including, Dondorp W, de Wert G, et al. Lifestyle-related factors and access to medically assisted reproduction. Hum Reprod 2010; 25:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/30\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Child-rearing ability and the provision of fertility services. Fertil Steril 2009; 92:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/31\">",
"      Pandey S, Maheshwari A, Bhattacharya S. Should access to fertility treatment be determined by female body mass index? Hum Reprod 2010; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/32\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons. Fertil Steril 2009; 92:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/33\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Human immunodeficiency virus and infertility treatment. Fertil Steril 2004; 82 Suppl 1:S228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/34\">",
"      Welmerink DB, Voigt LF, Daling JR, Mueller BA. Infertility treatment use in relation to selected adverse birth outcomes. Fertil Steril 2010; 94:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17287/abstract/35\">",
"      Jaques AM, Amor DJ, Baker HW, et al. Adverse obstetric and perinatal outcomes in subfertile women conceiving without assisted reproductive technologies. Fertil Steril 2010; 94:2674.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7396 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17287=[""].join("\n");
var outline_f16_56_17287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVALENCE OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAUSES OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WHO SHOULD PERFORM THE INFERTILITY EVALUATION?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TIMING OF INFERTILITY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INFERTILITY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7396|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/24/11661\" title=\"figure 1\">",
"      Fecundability in healthy couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/54/34671\" title=\"figure 2\">",
"      IVF outcome by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29675\" title=\"table 1\">",
"      Indications and timing of the infertility evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/63/20476\" title=\"table 2\">",
"      Infertility evaluation - history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=related_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/52/22343?source=related_link\">",
"      Psychological stress and infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17288="Percutaneous transtracheal ventilation procedure";
var content_f16_56_17288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Needle cricothyroidotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 588px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Performing needle cricothyroidotomy. A) The needle is angled caudally at 30 to 45 degrees and inserted through the cricothyroid membrane until bubbles are seen in the fluid-filled syringe, indicating puncture of the trachea. B) The catheter is advanced to the hub as the needle and syringe are removed. C) The catheter is secured in place and connected to the oxygen delivery system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17288=[""].join("\n");
var outline_f16_56_17288=null;
var title_f16_56_17289="Giant cell arteritis light";
var content_f16_56_17289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant cell arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temporal artery biopsy in giant cell (temporal) arteritis. Left panel: Granulomatous and lymphocytic inflammation of the adventitia and medial wall of the temporal artery. Right panel: Elastic tissue stain showing disruption of the elastica (arrows) due to immunologically mediated destruction of the elastica.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17289=[""].join("\n");
var outline_f16_56_17289=null;
var title_f16_56_17290="Neuroimaging of acute ischemic stroke";
var content_f16_56_17290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuroimaging of acute ischemic stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Jamary Oliveira-Filho, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Walter J Koroshetz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Eric D Schwartz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/56/17290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/56/17290/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/56/17290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are used to exclude hemorrhage in the acute stroke patient, to assess the degree of brain injury, and to identify the vascular lesion responsible for the ischemic deficit. Some advanced CT and MRI technologies are able to distinguish between brain tissue that is irreversibly infarcted and that which is potentially salvageable, thereby allowing better selection of patients likely to benefit from therapy. The use of this technology is dependent upon availability, and its role in guiding treatment decisions is still under study.",
"   </p>",
"   <p>",
"    Neuroimaging during the acute phase (first few hours) of an ischemic stroke will be reviewed here. Other aspects of the acute evaluation of stroke, the clinical diagnosis of various types of stroke, and the subacute and long-term assessment of patients who have had a stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantages of computed tomography (CT) are widespread access and speed of acquisition. In the hyperacute phase, a non-contrast CT (NCCT) scan is usually ordered to exclude or confirm hemorrhage; it is highly sensitive for this indication. A NCCT scan should be obtained as soon as the patient is medically stable. The presence of hemorrhage leads to very different management and concerns than a normal scan or one that shows infarction. Immediate CT scanning of all patients with suspected stroke is also the most cost-effective strategy when compared with alternate strategies such as scanning selected patients or delayed rather than immediate imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of CT for acute stroke has been enhanced by the advent of additional CT techniques including CT perfusion imaging (CTP) and CT angiography (CTA). Multimodal CT evaluation that employs the three techniques (NCCT, CTA and CTP) combined shows improved detection of acute infarction when compared with NCCT evaluation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition, multimodal evaluation that includes CTA and CTP may permit assessment of the site of vascular occlusion, infarct core, salvageable brain tissue and degree of collateral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early signs of infarction on noncontrast CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of standard noncontrast CT for brain ischemia increases after 24 hours. However, in a systematic review involving 15 studies where CT scans were performed within six hours of stroke onset, the prevalence of early CT signs of brain infarction was 61 percent (standard deviation",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early signs of infarction include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoattenuation involving one-third or more of the middle cerebral artery (MCA) territory",
"     </li>",
"     <li>",
"      Obscuration of the lentiform nucleus",
"     </li>",
"     <li>",
"      Cortical sulcal effacement",
"     </li>",
"     <li>",
"      Focal parenchymal hypoattenuation",
"     </li>",
"     <li>",
"      Loss of the insular ribbon or obscuration of the Sylvian fissure",
"     </li>",
"     <li>",
"      Hyperattenuation of large vessel (eg, \"hyperdense MCA sign\")",
"     </li>",
"     <li>",
"      Loss of gray-white matter differentiation in the basal ganglia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of early CT signs of infarction implies a worse prognosis. In the systematic review, the presence of these signs was associated with an increased risk of poor functional outcome (odds ratio 3.11, 95% CI 2.77-3.49) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperdensity of the MCA, indicating the presence of thrombus inside the artery lumen (bright artery sign), can be visualized on noncontrast CT in 30 to 40 percent of patients with an MCA distribution stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. This finding is highly specific for MCA occlusion, although it may be less useful for predicting outcome than the other early CT signs.",
"   </p>",
"   <p>",
"    While early CT signs of infarction are associated with a worse outcome, it remains unclear whether early infarction signs should be considered when deciding whether to use intravenous (IV) thrombolytic treatment for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/7\">",
"     7",
"    </a>",
"    ]. An analysis from the NINDS trial found that early CT signs of infarction were not independently associated with increased risk of adverse outcome after IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment, and patients treated with alteplase did better whether or not they had early CT signs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H32#H32\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful attention to the presence of these signs by experienced personnel is necessary; mistakes have occurred in up to 20 percent of cases in a controlled setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/14\">",
"     14",
"    </a>",
"    ]. Studies that have examined the ability of neurologists, neuroradiologists, and general practitioners have found that early infarction can be very difficult to recognize on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the importance of a truly normal head CT in acute stroke should not be underestimated; it excludes major ischemic damage with high specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standardized methods such as ASPECTS have been developed to aid recognition of early ischemia because of the known difficulty in detecting such changes. In addition, accentuating the contrast between normal and edematous (ischemic) brain tissue by variable window width and center level settings may improve detection of early ischemic change on noncontrast CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ASPECTS method of assessing ischemic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Alberta stroke program early CT score (ASPECTS) was developed to provide a simple and reliable method of assessing ischemic changes on head CT scan in order to identify acute stroke patients unlikely to make an independent recovery despite thrombolytic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ASPECTS value is calculated from two standard axial CT cuts; one at the level of the thalamus and basal ganglia, and one just rostral to the basal ganglia (",
"    <a class=\"graphic graphic_figure graphicRef72190 \" href=\"UTD.htm?12/0/12294\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63480 \" href=\"UTD.htm?10/41/10903\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The score divides the middle cerebral artery (MCA) territory into 10 regions of interest.",
"     </li>",
"     <li>",
"      Subcortical structures are allotted three points (one each for caudate, lentiform nucleus, and internal capsule).",
"     </li>",
"     <li>",
"      MCA cortex is allotted seven points. Four of these points come from the axial CT cut at the level of the basal ganglia, with one point for insular cortex and one point each for M1, M2, and M3 regions (anterior, lateral, and posterior MCA cortex).",
"     </li>",
"     <li>",
"      Three points come from the CT cut just rostral to the basal ganglia, with one point each for M4, M5, and M6 regions (anterior, lateral, and posterior MCA cortex).",
"     </li>",
"     <li>",
"      One point is subtracted for an area of early ischemic change, such as focal swelling or parenchymal hypoattenuation, for each of the defined regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, a normal CT scan has an ASPECTS value of 10 points, while diffuse ischemic change throughout the MCA territory gives a value of 0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Utility of ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial ASPECTS study, pretreatment noncontrast head CT scans from 156 patients with anterior circulation ischemia treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (t-PA) were prospectively scored with ASPECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/18\">",
"     18",
"    </a>",
"    ]. The following observations were made for baseline values.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ASPECTS was inversely correlated with stroke severity.",
"     </li>",
"     <li>",
"      The median ASPECTS value was 8; a value of 7 or less was associated with a sharp increase in dependence and death at three months.",
"     </li>",
"     <li>",
"      ASPECTS predicted functional outcome and symptomatic intracerebral hemorrhage, with good sensitivity and specificity for functional outcome (0.78 and 0.96) and for ICH (0.90 and 0.61).",
"     </li>",
"     <li>",
"      The inter- and intraobserver reliability was good to excellent; score reliability appears to be good when performed in real time by treating physicians as compared with expert readers [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective study of 100 patients with acute ischemic stroke, the ability to detect early ischemic changes by ASPECTS was similar on noncontrast CT and diffusion-weighted imaging (DWI) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ASPECTS has been retrospectively applied to baseline and 24-hour CT scans for patients with middle cerebral artery occlusion who were randomized to intraarterial thrombolysis or placebo in the PROACT-II study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/22\">",
"     22",
"    </a>",
"    ]. Treated patients with a baseline ASPECTS &gt;7 had a risk ratio (RR) of 3.2 (95% CI 1.2-9.1) for an independent functional outcome, while patients with ASPECTS &le;7 had a RR of 1.0 (95% CI 0.6-1.9).",
"   </p>",
"   <p>",
"    Despite its promise, the available data suggest that ASPECTS analysis of noncontrast CT does",
"    <strong>",
"     not",
"    </strong>",
"    identify patients who may benefit from thrombolysis. The prospective CASES observational cohort study of 1135 patients treated with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    found that each one point decrement in the baseline ASPECTS scores was associated with a lower probability of independent functional outcome (odds ratio 0.81, 95% CI 0.75-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the ASPECTS score was not a predictor of symptomatic intracranial hemorrhage in patients treated within the standard three-hour time window.",
"   </p>",
"   <p>",
"    Subsequent reports showed that the ASPECTS score of baseline noncontrast CT scans from the NINDS and ECASS-II tPA stroke studies was not associated with a statistically significant modification of tPA treatment effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This finding is in agreement with a report cited above from the NINDS cohort, which found that signs of early ischemic change on CT were not independently associated with increased risk of adverse outcome after IV tPA treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Early signs of infarction on noncontrast CT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One problem with ASPECTS may be that the various types of parenchymal changes on noncontrast CT considered to represent early ischemic change may actually have different pathophysiologic mechanisms. In particular, there is evidence suggesting that hypoattenuation represents irreversible infarction, whereas focal swelling may represent penumbral tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. ASPECTS may have greater accuracy for detection of ischemic change and for identifying final infarct volume when used to analyze CTA-source images and the contrast CT images obtained from CTP than when used to analyze noncontrast CT images [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Utility of CT contrast dye'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'CT perfusion imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to note that ASPECTS is not applicable to lacunar stroke, brainstem stroke, or any stroke outside of the middle cerebral artery territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Utility of CT contrast dye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiral (helical) CT and new generation multidetector CT scanners increase scan speed and allow CT angiography (CTA) of both extracranial and intracranial cerebral arteries. The speed of these CT units also offers CT perfusion (CTP) capabilities. These scans can be performed immediately after conventional CT scanning, requiring only 5 to 10 minutes of additional time. In practice, one can perform both CTA and CTP during the same examination, with separate contrast boluses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of these fast CT scans include the ability to rapidly identify patients with occlusion of the major vessels within the circle of Willis or extracranial cerebral arteries, as well as the ability to evaluate the perfusion status of the brain parenchyma. Additional information about brain perfusion can be obtained by post imaging analysis of the raw data (or source images) of CTA and CTP studies. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'CT angiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'CT perfusion imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT angiography (CTA) is performed by administering a rapid bolus of standard intravenous CT contrast through a large bore intravenous line in the antecubital fossa. The helical CT scan is timed to capture the arrival of dye into the brain. Dye can be seen in the great vessels on the raw CT images; these serve as data for three dimensional computer reconstructions of the circle of Willis and extracranial cerebral arteries. Clot causes a filling defect in the vessel on CTA, which often can be seen on the raw images (also called source images). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"     \"Principles of computed tomography of the chest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the detection of intracranial large vessel stenosis and occlusion, CTA in various studies had sensitivities of 92 to 100 percent and specificities of 82 to 100 percent when compared with conventional angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/30\">",
"     30",
"    </a>",
"    ]. The accuracy of CTA for the diagnosis of extracranial carotid stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of carotid artery stenosis\", section on 'CT angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recanalization rates for intravenous or intraarterial thrombolysis differ depending upon the site of arterial occlusion. CTA has become the standard of practice in our center to triage patients between intravenous or intraarterial thrombolysis. It is also helpful in diagnosing stroke mimics. As an example, the patient with severe brainstem signs thought due to basilar thrombosis who has a normal basilar artery on CTA demands an alternative diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     CTA source images",
"    </span>",
"    &nbsp;&mdash;&nbsp;CTA source images can provide an estimate of perfusion by taking advantage of the contrast enhancement in the brain vasculature that occurs during a CTA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/31\">",
"     31",
"    </a>",
"    ], potentially obviating the need for a separate CT perfusion study and a second contrast bolus. CTA source images typically cover the entire brain, in contrast to CT perfusion source images that are limited to a few brain slices.",
"   </p>",
"   <p>",
"    During a CTA, contrast dye fills the brain microvasculature in the normal perfused tissue that is accessible to the blood pool and appears as increased signal intensity on the CTA source images. In distinction, contrast dye does not fill the microvasculature in ischemic brain regions that are less accessible to the blood pool and have poor collateral flow. These ischemic areas are easily seen as regions of hypoattenuation (low density or dark) on CTA source images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54188 \" href=\"UTD.htm?28/41/29336\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CTA source images are more sensitive than noncontrast CT scans for the detection of early brain infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/30,34\">",
"     30,34",
"    </a>",
"    ]. Hypoattenuation on CTA source images correlates with ischemic edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/33\">",
"     33",
"    </a>",
"    ], and with the abnormality on diffusion-weighted MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/35\">",
"     35",
"    </a>",
"    ]. In this sense, CTA source images (or raw images of CT perfusion studies) can be considered as a surrogate for DWI. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diffusion-weighted imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CT perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using an intravenous bolus of CT dye, a whole brain \"perfused blood volume map\" can be obtained by timing the scan to the passage of the contrast dye through the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/36\">",
"     36",
"    </a>",
"    ]. This can be obtained by continuing to scan the brain during a CT angiogram or by using a new bolus of contrast following the CTA. However, CTP requires repeatedly scanning the same portion of the brain parenchyma over the time required for the bolus to pass through the vasculature. Therefore, CTP is limited to imaging only a few slices through the brain, potentially missing important volumes of ischemic parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/37\">",
"     37",
"    </a>",
"    ]. The number of slices that CTP can image is likely to increase with newer generation multidetector CT scanners.",
"   </p>",
"   <p>",
"    Similar to CTA-SI, the source images of the CTP (CTP-SI) are available for analysis. As with CTA-SI, areas of hypoattenuation on CTP-SI should correlate with ischemic brain regions. In addition, quantitative analysis of the kinetics of a bolus of CT dye passing through the brain enable estimation of cerebral blood flow (CBF), cerebral blood volume (CBV), and the mean transit time (MTT) that it takes blood to flow through the tissue. Thresholds of CBF and CBV can be used to predict whether tissue will die or survive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that the ASPECTS method applied to CTP-SI or CBV maps was more accurate for identifying irreversible ischemia and clinical outcome than ASPECTS applied to noncontrast CT or CTA-SI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, ASPECTS applied to CBF maps or MTT appeared to identify the maximal extent of infarction in the absence of major reperfusion, and the difference between CTP-SI (or CBV) and CBF (or MTT) on ASPECTS appeared to identify ischemic tissue at risk for infarction. Thus, ASPECTS applied to CTP and its multiple parametric maps (CBV, CBV, MTT) holds promise for improving patient selection for intravenous thrombolysis of acute ischemic stroke, and for extending the time window beyond three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. However, this hypothesis should be confirmed in randomized clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced MRI imaging techniques have the potential for further defining stroke subgroup populations that may benefit from intravenous thrombolysis or interventional vascular treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, MRI sequences using high susceptibility methods, such as gradient echo (GRE) pulse sequences, are equivalent to CT for the detection of acute intracerebral hemorrhage (ICH) and better than CT for the detection of chronic hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. ICH can be diagnosed by MRI with up to 100 percent sensitivity and accuracy by experienced readers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H2513592#H2513592\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage appearance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain MRI protocols that combine conventional T1 and T2 sequences with diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), and GRE can reliably diagnose both acute ischemic stroke and acute hemorrhagic stroke in emergency settings. These MRI techniques may obviate the need for emergent CT in centers where brain MRI is readily available. As an example, one specialized stroke center found that routine use of these MRI sequences to screen patients prior to intravenous thrombolysis for suspected ischemic stroke was practical and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/44\">",
"     44",
"    </a>",
"    ]. Furthermore, MRI screening did not cause excessive treatment delays or lead to worse outcomes. On the other hand, MRI-specific selection criteria for acute thrombolysis of ischemic stroke have not been validated, and no randomized studies have compared CT and MRI screening in this setting.",
"   </p>",
"   <p>",
"    Newer ultrafast MRI imaging protocols can reduce acquisition times from the 15 to 20 minutes required by conventional MRI to five minutes or less, but the utility of these newer methods is not yet established [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diffusion-weighted imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion-weighted imaging (DWI) is based upon the capacity of fast MRI to detect a signal related to the movement of water molecules between two closely spaced radiofrequency pulses. This technique can detect abnormalities due to ischemia within 3 to 30 minutes of onset, [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], when conventional MRI and CT images would still appear normal.",
"   </p>",
"   <p>",
"    In acute stroke, swelling of the ischemic brain parenchymal cells follows failure of the energy-dependent",
"    <span class=\"nowrap\">",
"     Na+/K",
"    </span>",
"    + &ndash; ATPase pumps and is believed to increase the ratio of intracellular to extracellular volume fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DWI contains an additional component of T2 effect, and increased T2 signal due to vasogenic edema can \"shine through\" on DWI images, making it difficult to distinguish vasogenic from cytotoxic edema on these images. This problem can be overcome by use of the apparent diffusion coefficient (ADC). The ADC provides a quantitative measure of the water diffusion. In acute ischemic stroke with cytotoxic edema, decreased water diffusion in infarcted tissue causes increased (hyperintense) DWI signal and a decreased ADC, visualized as hypointense signal on ADC maps of the brain. In contrast, vasogenic edema may cause increased DWI signal may occur due to T2 shine through, but water diffusion is increased, and increased ADC is seen as hyperintense signal on ADC maps.",
"   </p>",
"   <p>",
"    The decrease in ADC in the region of the infarct is a necessary transition on the way to infarction. The decrease in diffusion in the infarct is transient, lasting one to two weeks. It then actually reverses, passing through a phase of pseudonormalization and later becoming elevated and bright on ADC maps [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/51\">",
"     51",
"    </a>",
"    ]. DWI abnormalities last somewhat longer due to the prominent T2 effect, but chronic infarction is not bright on DWI.",
"   </p>",
"   <p>",
"    In a study comparing CT, DWI, and standard MRI, we found that abnormal DWI was a sensitive and specific indicator of ischemic stroke in patients presenting within six hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/52\">",
"     52",
"    </a>",
"    ]. Others have confirmed these results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, occasional patients with acute ischemic deficits have a normal DWI, but follow-up MRI or CT confirms an infarct [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In some of these patients, the stroke was a small brainstem lacune; in others, ischemia was seen on perfusion MRI in regions that had not yet become abnormal on DWI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MR and DWI utilizing higher magnetic field strengths of 3 Tesla (T) units are increasingly available in clinical settings. However, there is only limited and conflicting evidence regarding whether DWI obtained using 3 T MRI scanners is better for the detection of early (&le;6 hours) and small infarcts compared with standard 1.5 T MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Although seemingly advantageous because of improved signal-to-noise ratios, higher magnetic field strengths also introduce increased imaging artifacts and geometric distortions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/60\">",
"     60",
"    </a>",
"    ], and these artifacts may obscure early ischemic changes, particularly in regions of brain near the skull base [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, further refinement of higher field strength DWI imaging is needed to determine if such imaging is useful in acute ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical utility of DWI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review published in 2010 from the American Academy of Neurology concluded that diffusion-weighted imaging (DWI) is superior to noncontrast CT for the diagnosis of acute ischemic stroke in patients presenting within 12 hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/61\">",
"     61",
"    </a>",
"    ]. Although based on weaker evidence, the AAN concluded that DWI may be useful for predicting late clinical outcome as measured by the National Institutes of Health Stroke Scale and the Barthel Index.",
"   </p>",
"   <p>",
"    Even in patients with subacute ischemic stroke who delay seeking medical attention, DWI may add clinically useful information to standard MRI. In a prospective observational study of 300 patients with suspected stroke or TIA and a median delay of 17 days from symptom onset, DWI compared with T2 provided additional clinical information imaging for 108 patients (36 percent) such as clarification of diagnosis or vascular territory; this was considered likely to change management in 42 patients (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the evaluation of acute ischemic stroke or TIA, the presence of multiple DWI lesions on the baseline MRI scan is associated with an increased risk of early lesion recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Furthermore, the presence of multiple DWI lesions of varying ages, as determined by the ADC value, is an independent predictor of future ischemic events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Perfusion-weighted imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion-weighted imaging reveals evidence of ischemic injury, not ischemia itself. In contrast, perfusion-weighted imaging (PWI) uses fast MRI techniques to quantify the amount of MR contrast agent reaching the brain tissue after a fast intravenous bolus. Integration of the amount of gadolinium entering the brain on first pass allows construction of maps of cerebral blood volume. Analysis that also includes the time course of arrival and washout permits the construction of maps of relative cerebral blood flow and mean transit time. The latter sensitively identifies the ischemic zone.",
"   </p>",
"   <p>",
"    PWI can be performed with standard MRI and MR angiography, requiring a total imaging time of less than 15 minutes. Access to MRI is usually the limiting factor.",
"   </p>",
"   <p>",
"    Another method of MRI perfusion imaging is continuous arterial spin labeling (CASL). Instead of using an intravascular contrast agent, CASL magnetically labels the blood entering the brain. CASL imaging within 24 hours of stroke symptom onset can depict perfusion defects and diffusion-perfusion mismatches [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, cerebral blood flow asymmetry on CASL appears to correlate with stroke severity and outcome.",
"   </p>",
"   <p>",
"    Guidelines from the American Academy of Neurology published in 2010 concluded that the baseline lesion volume on PWI may predict baseline stroke severity, but found that evidence was insufficient to support or refute the utility of PWI for use in diagnosing acute ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Identifying reversible ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate identification of patients with reversible ischemic injury in the brain is important for selecting those patients most likely to benefit and least likely to be harmed by reperfusion and neuroprotective therapy. In patients with acute stroke, there are often areas that are ischemic but do not yet appear abnormal by DWI or ADC maps on early scans. Regions with decreased cerebral blood volume are usually involved in the final infarct, while regions with normal cerebral blood volume but low cerebral blood flow and increased mean transit time may or may not survive the ischemic insult.",
"   </p>",
"   <p>",
"    The expectation that PWI and DWI could reliably define the ischemic penumbra and infarct core in acute stroke is still unrealized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/68\">",
"     68",
"    </a>",
"    ]. Although PWI can reveal the ischemic zone, the thresholds of PWI derived cerebral blood flow and volume that might discriminate the ischemic penumbra from infarct core have not been definitively established [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/69\">",
"     69",
"    </a>",
"    ]. And while DWI can often reveal irreversibly infarcted tissue, it is now clear that some DWI lesions represent injured but still viable tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In addition, while some cases manifest with a &ldquo;classic&rdquo; mismatch pattern where the ischemic core on DWI is embedded within a hypoperfused penumbral brain region on PWI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82701 \" href=\"UTD.htm?3/21/3415\">",
"     image 2",
"    </a>",
"    ), others show a &ldquo;nonclassic&rdquo; fragmented mismatch pattern in which part or all of the ischemic region on DWI is dissociated from the hypoperfused region on PWI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72178 \" href=\"UTD.htm?26/10/26789\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consensus guidelines from the American Heart Association published in 2003 concluded that no recommendation could be given to employ PWI either to guide the use of thrombolysis or predict resulting complications such as postthrombolytic hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/75\">",
"     75",
"    </a>",
"    ]. A subsequent review evaluated MRI methods for selecting patients for thrombolysis and concluded that although DWI and PWI thresholds can delineate areas of brain with higher probability of infarction or salvage, their precise role in acute stroke management is not yet settled [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, DWI and PWI have clear utility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe perfusion defects in areas with a diffusion-perfusion",
"      <span class=\"nowrap\">",
"       (DWI/PWI)",
"      </span>",
"      mismatch may be a risk factor for lesion enlargement [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with an occluded artery are at a higher risk for lesion enlargement by growth of infarction into areas of perfusion deficit, implying that early recanalization (either spontaneously or with thrombolytic agents) may prevent lesion growth [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal volumes on DWI and PWI during an acute stroke correlate well with initial NIH stroke scale scores, chronic scores, and final lesion volume, and also may predict early neurologic deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Significant correction of focal brain hypoperfusion on PWI after tPA can predict excellent outcome at three months in ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with acute ischemic stroke may in theory be selected for thrombolytic therapy based on",
"      <span class=\"nowrap\">",
"       DWI/PWI",
"      </span>",
"      mismatch, thereby allowing extension of the conventional 3 hour window of opportunity for acute stroke thrombolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"       \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique of cerebrospinal fluid-suppressed apparent diffusion coefficient (ADC) measurements can reduce the false elevation of ADC that results from CSF artifact and allow for a more accurate identification of ischemic tissue at risk for infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/85\">",
"     85",
"    </a>",
"    ]. This information may ultimately be most useful in identifying risk groups of patients who would benefit from various therapies such as thrombolysis in the acute setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     MR angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR angiography (MRA) to detect vascular stenosis or occlusion is done at many centers as part of a fast MRI protocol for acute ischemic stroke. Results from a case series showed that the combined use of DWI with MRA within 24 hours of hospitalization substantially improved the early diagnostic accuracy of ischemic stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast-enhanced MRA shows promise for improved imaging of intracranial large vessels compared with the more established time of flight (TOF) technique [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/87\">",
"     87",
"    </a>",
"    ]. For the detection of intracranial large vessel stenosis and occlusion, contrast-enhanced MRA in various studies had sensitivities of 86 to 97 percent and specificities of 62 to 91 percent when compared with conventional angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/30\">",
"     30",
"    </a>",
"    ]. The accuracy of MRA for the diagnosis of extracranial carotid stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of carotid artery stenosis\", section on 'MR angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     High susceptibility sequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence supports the utility of high susceptibility MRI sequences (ie, gradient echo (GRE) or T2* weighted images) for the early detection of acute thrombosis and occlusion involving the middle cerebral (MCA) or internal carotid artery (ICA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Acute thrombotic occlusion may appear on high susceptibility MRI as a hypointense (dark) signal within the MCA or ICA, often in a curvilinear shape; the diameter of the hypointense signal is larger than that of the contralateral unaffected vessel. This finding is called the susceptibility sign, and it is analogous to the hyperdense MCA sign described for CT imaging. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Computed tomography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a retrospective report of 42 patients with stroke in the MCA territory who had MR imaging 95 to 360 minutes from stroke onset, a positive susceptibility sign corresponding to MCA or ICA occlusion was found in 30 (71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/89\">",
"     89",
"    </a>",
"    ]. The specificity of the sign was 100 percent. The overall sensitivity was 83 percent compared with MR angiography but varied widely depending on location, from 38 percent for occlusions distal to the MCA bifurcation to 97 percent for occlusions proximal to the MCA trunk. Patients who had positive susceptibility signs had significantly higher NIHSS scores (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"UTD.htm?39/33/40477\">",
"     table 1",
"    </a>",
"    ) compared with patients who did not have the sign, but no significant differences were found for infarct volume.",
"   </p>",
"   <p>",
"    High susceptibility MRI sequences are also useful for the detection of acute intraparenchymal hemorrhage, especially if this is a concern after intra-arterial therapy, a situation where retained contrast is not easily distinguished from blood on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H2513592#H2513592\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage appearance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CT VERSUS MRI TECHNIQUES IN HYPERACUTE STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of very early neuroimaging are to exclude hemorrhage or stroke mimics, detect signs of early infarction, depict the infarct core and extent of perfusion deficit, reveal the status of large cervical and intracranial arteries, and guide treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/91\">",
"     91",
"    </a>",
"    ]. As already noted, diffusion-weighted MRI (DWI) is more sensitive than CT for the early detection of acute ischemia, and high susceptibility MRI sequences such as gradient echo (GRE) are now known to be as good as CT for the detection of acute hemorrhage. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These points are illustrated by a prospective single-center study that evaluated 356 patients referred because of suspicion for acute stroke irrespective of time from symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/54\">",
"     54",
"    </a>",
"    ]. Of these, 217 had a final clinical diagnosis of acute stroke. All 356 patients had both brain MRI (employing DWI and GRE) and head CT, with median times from symptom onset to scanning of 6.1 and 6.5 hours, respectively. Assessment of all brain images was blinded to clinical information.",
"   </p>",
"   <p>",
"    The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute ischemic stroke was detected in more patients by MRI than by CT (46 versus 10 percent), a difference that was statistically significant",
"     </li>",
"     <li>",
"      Acute intracranial hemorrhage detection was similar with MRI and CT (6 versus 7 percent)",
"     </li>",
"     <li>",
"      The sensitivity for the detection of any acute stroke was much greater for MRI than for CT (83 versus 26 percent), while specificity was similar (98 versus 97 percent)",
"     </li>",
"     <li>",
"      Contraindications to MRI (eg, electronic implants, patient intolerance, or medical instability) led to the exclusion of about 11 percent of the 450 patients screened for this study",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that MRI can be used as the only imaging method for patients with suspected acute ischemic or hemorrhagic stroke who have no MRI contraindications.",
"   </p>",
"   <p>",
"    Limited evidence suggests that the utility of head CT, when performed with CTP, may be equal to that of MRI in hyperacute stroke evaluation, as found in a study of 22 patients who were evaluated using both CT and MRI techniques within six hours of stroke onset (average time interval of 2.33 hours for CT and 3.0 hours for MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/92\">",
"     92",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perfusion lesion volumes derived by CTP did not differ from those derived by PWI for both time to peak maps and cerebral blood volume maps.",
"     </li>",
"     <li>",
"      CTA-SI ischemic lesion volumes did not differ from DWI ischemic lesion volumes.",
"     </li>",
"     <li>",
"      Lesion volumes on CTP cerebral blood flow maps significantly correlated with lesion volumes on follow-up non-contrast CT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have shown that the CTP derived map of CBV correlates with the MRI DWI lesion size [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/35\">",
"     35",
"    </a>",
"    ] and is predictive of infarcted brain tissue that is not salvageable despite reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many more patients considered for the study were eligible for contrast-enhanced CT than for MRI (93 versus 58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/92\">",
"     92",
"    </a>",
"    ]. This reflects the well-known problem that MRI in practice is more limited by patient contraindications or intolerance than CT. In addition, MRI is less widely available than CT outside of major stroke centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ULTRASOUND METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid Duplex ultrasound (CDUS) and transcranial Doppler (TCD) ultrasound are noninvasive methods for neurovascular evaluation of the extracranial and intracranial large vessels. Carotid and vertebral Duplex and TCD have traditionally been used independently in an elective fashion to evaluate patients with TIA and ischemic stroke of possible large artery origin.",
"   </p>",
"   <p>",
"    Although both methods may help to establish the source of an embolic stroke, they have rarely been used acutely for this purpose. However, accumulating evidence suggests that both Duplex and TCD can be used urgently at the bedside to select patients for interventional thrombolytic or endovascular treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Combined duplex and TCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Carotid and vertebral duplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color flow guided duplex ultrasound is well established as a noninvasive examination to evaluate extracranial atherosclerotic disease. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Transcranial Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial Doppler (TCD) ultrasound uses low frequency (2 MHz) pulsed sound to penetrate bony windows and visualize intracranial vessels of the circle of Willis. Its use has gained wide acceptance in stroke and neurologic intensive care units as a noninvasive means of assessing the patency of intracranial vessels.",
"   </p>",
"   <p>",
"    In patients with acute stroke, TCD is able to detect intracranial stenosis, identify collateral pathways, detect emboli on a real-time basis, and monitor reperfusion after thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. Major drawbacks include examiner-dependence, poor patient windows (unable to insonate a flow signal in 15 percent of cases), and low sensitivity in the vertebrobasilar system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combined duplex and TCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of urgent duplex and TCD appears to have high utility when performed by skilled ultrasonographers, although the available data come mainly from small studies. As an example, a study of 150 patients found that the detection of arterial lesions amenable to interventional treatment (LAITs) by combined duplex and TCD (n=150) at mean time of 128 minutes after stroke or TIA onset was 100 percent sensitive and specific compared with digital subtraction angiography (DSA, n=30) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/100\">",
"     100",
"    </a>",
"    ]. The combination of duplex and TCD detected LAITs in 96 percent of patients eligible for thrombolysis. Accuracy of the individual components was lower but still good; duplex ultrasound had a sensitivity and specificity of 96 and 90 percent compared with DSA, while that of TCD was 96 and 75 percent. About 10 percent of patients had incomplete TCD studies because of inadequate temporal windows.",
"   </p>",
"   <p>",
"    A major limitation of this approach is that most centers are unable to perform examinations acutely because they lack sufficient numbers of experienced ultrasonographers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CONVENTIONAL ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital subtraction angiography, the most widely used method of conventional catheter-based angiography, remains the gold standard for evaluating the cerebral vessels with regard to determining the degree of arterial stenosis and the presence of dissection, vasculopathy, vasculitis, or occult lesions such as vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, it provides information about collateral flow and perfusion status.",
"   </p>",
"   <p>",
"    Nevertheless, diagnostic conventional angiography is rarely performed in the acute setting for two main reasons. One is the availability of the noninvasive techniques - CT angiography, MR angiography, duplex ultrasonography, and transcranial Doppler ultrasound - to rapidly visualize intracranial and extracranial arterial disease. The other is the risk of stroke, albeit low, associated with conventional angiography.",
"   </p>",
"   <p>",
"    The major exception is suspected large vessel occlusion; angiography is more sensitive than noninvasive methods in these cases and offers the potential for \"in-situ\" treatment. In addition, angiography shows promise when combined with neurointerventional techniques for acute intraarterial thrombolysis and angioplasty.",
"   </p>",
"   <p>",
"    The main drawback to conventional cerebral angiography is the risk of stroke (0.14 to 1 percent) and transient ischemia (0.4 to 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/101-106\">",
"     101-106",
"    </a>",
"    ]. The risk of neurologic complications appears to be higher in patients &ge;55 years of age, in patients with atherosclerotic cerebrovascular disease or cardiovascular disease, and with fluoroscopic time &ge;10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Clinically silent embolism as detected by diffusion-weighted magnetic resonance imaging (DWI) may occur in up to 25 percent of cerebral angiographic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The rate of clinically silent embolism may be reduced by use of air filters and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/109\">",
"     109",
"    </a>",
"    ], but it is unclear if such methods reduce the more important clinical parameter of ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are based upon the available literature, consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/56/17290/abstract/30,110\">",
"     30,110",
"    </a>",
"    ], and clinical experience.",
"   </p>",
"   <p>",
"    Brain imaging plays a vital role in acute stroke by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delineating ischemia from hemorrhage",
"     </li>",
"     <li>",
"      Estimating tissue at risk for infarction",
"     </li>",
"     <li>",
"      Excluding some stroke mimics, such as tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Head CT is the preferred imaging study at most centers because of widespread availability, rapid scan times, and ease of detecting intracranial hemorrhage. MRI has an advantage in the very early detection of ischemia with DWI imaging, and it reliably detects hyperacute hemorrhage with proper sequences including high susceptibility images.",
"   </p>",
"   <p>",
"    Advances in the use of CTA source images and CTP suggest that CT techniques are increasingly able to provide crucial information regarding early ischemia and perfusion lesions in hyperacute stroke assessment. CT remains indispensable in the frequent circumstance where there are contraindications to MRI such as pacemakers and patient intolerance due to anxiety or motion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain imaging and a comprehensive neurovascular evaluation should be obtained for most patients suspected of having acute ischemic stroke or transient ischemic attack. Neurovascular imaging is important in acute stroke to determine the potential sources of embolism or low flow in ischemic stroke and to detect possible aneurysms or vessel malformations in hemorrhagic stroke.",
"     </li>",
"     <li>",
"      Brain imaging is required to guide the selection of acute interventions to treat patients with stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"       \"Initial assessment and management of acute stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"       \"Reperfusion therapy for acute ischemic stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link\">",
"       \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain imaging in acute ischemic stroke can be obtained with either noncontrast head CT or conventional MRI. Both imaging techniques can be used to exclude acute intracerebral hemorrhage. Brain MRI with diffusion imaging is superior to noncontrast CT for the detection of acute ischemia and the exclusion of some stroke mimics. However, at present there are no data to show that MRI is superior to CT for selecting patients who could be treated with intravenous recombinant tissue plasminogen activator (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      ). Thus, MRI should be used rather than CT only if it does not unduly delay treatment with intravenous alteplase in an eligible patient.",
"     </li>",
"     <li>",
"      Where available, assessment of ischemic brain injury and brain perfusion status with either diffusion and perfusion MRI or with contrast CT source images and perfusion CT should be performed if the findings are likely to influence treatment decisions, such as acute thrombolysis or endovascular interventions.",
"     </li>",
"     <li>",
"      Neurovascular imaging should assess the extracranial (internal carotid and vertebral) and intracranial (internal carotid, vertebral, basilar, and Circle of Willis) large vessels. Noninvasive methods are preferred unless urgent endovascular therapy is planned. MRA, CTA, or the combination of ultrasound methods (Duplex and TCD) can be used. Conventional angiography is usually reserved for situations where acute intraarterial thrombolysis is being considered and for follow-up when noninvasive studies are inconclusive. Availability and expertise at individual centers is a major factor in the choice of the initial noninvasive neurovascular studies. A detailed comparison of the advantages and disadvantages of these studies for the diagnosis of carotid artery disease is found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"       \"Evaluation of carotid artery stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular imaging should not delay treatment using intravenous tPA (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      ) for eligible patients with acute ischemic stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"       \"Reperfusion therapy for acute ischemic stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In select patients, neurovascular imaging of the aortic arch, vertebral artery origins, and common carotid arteries should be considered if clinical suspicion for a proximal large artery source of stroke or TIA is high. Useful methods include CT angiography, time-of-flight MR angiography, and contrast enhanced MR angiography. In addition, transesophageal echocardiography is useful for assessing the aortic arch.",
"     </li>",
"     <li>",
"      The brain imaging and neurovascular studies should not be considered in isolation, but rather as one part of the acute stroke evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"       \"Initial assessment and management of acute stroke\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/1\">",
"      Wardlaw JM, Seymour J, Cairns J, et al. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 2004; 35:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/2\">",
"      Ezzeddine MA, Lev MH, McDonald CT, et al. CT angiography with whole brain perfused blood volume imaging: added clinical value in the assessment of acute stroke. Stroke 2002; 33:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/3\">",
"      Kloska SP, Nabavi DG, Gaus C, et al. Acute stroke assessment with CT: do we need multimodal evaluation? Radiology 2004; 233:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/4\">",
"      Hopyan J, Ciarallo A, Dowlatshahi D, et al. Certainty of stroke diagnosis: incremental benefit with CT perfusion over noncontrast CT and CT angiography. Radiology 2010; 255:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/5\">",
"      Tan JC, Dillon WP, Liu S, et al. Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol 2007; 61:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/6\">",
"      Wintermark M, Rowley HA, Lev MH. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro CT. Radiology 2009; 251:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/7\">",
"      Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic review. Radiology 2005; 235:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/8\">",
"      Truwit CL, Barkovich AJ, Gean-Marton A, et al. Loss of the insular ribbon: another early CT sign of acute middle cerebral artery infarction. Radiology 1990; 176:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/9\">",
"      von Kummer R, Meyding-Lamad&eacute; U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/10\">",
"      Marks MP, Holmgren EB, Fox AJ, et al. Evaluation of early computed tomographic findings in acute ischemic stroke. Stroke 1999; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/11\">",
"      Wijdicks EF, Diringer MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. Mayo Clin Proc 1998; 73:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/12\">",
"      Leys D, Pruvo JP, Godefroy O, et al. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992; 23:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/13\">",
"      Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001; 286:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/14\">",
"      Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/15\">",
"      Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PA. Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT? J Neurol Neurosurg Psychiatry 1999; 67:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/16\">",
"      von Kummer R, Bourquain H, Bastianello S, et al. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology 2001; 219:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/17\">",
"      Lev MH, Farkas J, Gemmete JJ, et al. Acute stroke: improved nonenhanced CT detection--benefits of soft-copy interpretation by using variable window width and center level settings. Radiology 1999; 213:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/18\">",
"      Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/19\">",
"      Pexman JH, Barber PA, Hill MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001; 22:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/20\">",
"      Coutts SB, Demchuk AM, Barber PA, et al. Interobserver variation of ASPECTS in real time. Stroke 2004; 35:e103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/21\">",
"      Barber PA, Hill MD, Eliasziw M, et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005; 76:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/22\">",
"      Hill MD, Rowley HA, Adler F, et al. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003; 34:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/23\">",
"      Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/24\">",
"      Demchuk AM, Hill MD, Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005; 36:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/25\">",
"      Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006; 37:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/26\">",
"      Na DG, Kim EY, Ryoo JW, et al. CT sign of brain swelling without concomitant parenchymal hypoattenuation: comparison with diffusion- and perfusion-weighted MR imaging. Radiology 2005; 235:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/27\">",
"      Butcher KS, Lee SB, Parsons MW, et al. Differential prognosis of isolated cortical swelling and hypoattenuation on CT in acute stroke. Stroke 2007; 38:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/28\">",
"      Coutts SB, Lev MH, Eliasziw M, et al. ASPECTS on CTA source images versus unenhanced CT: added value in predicting final infarct extent and clinical outcome. Stroke 2004; 35:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/29\">",
"      Parsons MW, Pepper EM, Chan V, et al. Perfusion computed tomography: prediction of final infarct extent and stroke outcome. Ann Neurol 2005; 58:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/30\">",
"      Latchaw RE, Alberts MJ, Lev MH, et al. Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke 2009; 40:3646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/31\">",
"      Hunter GJ, Hamberg LM, Ponzo JA, et al. Assessment of cerebral perfusion and arterial anatomy in hyperacute stroke with three-dimensional functional CT: early clinical results. AJNR Am J Neuroradiol 1998; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/32\">",
"      Lev MH, Segal AZ, Farkas J, et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 2001; 32:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/33\">",
"      Schramm P, Schellinger PD, Fiebach JB, et al. Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke 2002; 33:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/34\">",
"      Camargo EC, Furie KL, Singhal AB, et al. Acute brain infarct: detection and delineation with CT angiographic source images versus nonenhanced CT scans. Radiology 2007; 244:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/35\">",
"      Wintermark M, Reichhart M, Cuisenaire O, et al. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 2002; 33:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/36\">",
"      Allmendinger AM, Tang ER, Lui YW, Spektor V. Imaging of stroke: Part 1, Perfusion CT--overview of imaging technique, interpretation pearls, and common pitfalls. AJR Am J Roentgenol 2012; 198:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/37\">",
"      Michel P, Bogousslavsky J. Penumbra is brain: no excuse not to perfuse. Ann Neurol 2005; 58:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/38\">",
"      Wintermark M, Reichhart M, Thiran JP, et al. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002; 51:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/39\">",
"      Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/40\">",
"      K&ouml;hrmann M, Schellinger PD. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. Radiology 2009; 251:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/41\">",
"      Patel MR, Edelman RR, Warach S. Detection of hyperacute primary intraparenchymal hemorrhage by magnetic resonance imaging. Stroke 1996; 27:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/42\">",
"      Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 2004; 35:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/43\">",
"      Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004; 292:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/44\">",
"      Kang DW, Chalela JA, Dunn W, et al. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke 2005; 36:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/45\">",
"      Ringelstein EB. Ultrafast magnetic resonance imaging protocols in stroke. J Neurol Neurosurg Psychiatry 2005; 76:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/46\">",
"      U-King-Im JM, Trivedi RA, Graves MJ, et al. Utility of an ultrafast magnetic resonance imaging protocol in recent and semi-recent strokes. J Neurol Neurosurg Psychiatry 2005; 76:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/47\">",
"      Warach S, Gaa J, Siewert B, et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/48\">",
"      Sorensen AG, Buonanno FS, Gonzalez RG, et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 1996; 199:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/49\">",
"      Li F, Han S, Tatlisumak T, et al. A new method to improve in-bore middle cerebral artery occlusion in rats: demonstration with diffusion- and perfusion-weighted imaging. Stroke 1998; 29:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/50\">",
"      Beauchamp NJ Jr, Barker PB, Wang PY, vanZijl PC. Imaging of acute cerebral ischemia. Radiology 1999; 212:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/51\">",
"      Schlaug G, Siewert B, Benfield A, et al. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology 1997; 49:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/52\">",
"      Gonz&aacute;lez RG, Schaefer PW, Buonanno FS, et al. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology 1999; 210:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/53\">",
"      Fiebach JB, Schellinger PD, Jansen O, et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002; 33:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/54\">",
"      Chalela JA, Kidwell CS, Nentwich LM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007; 369:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/55\">",
"      Brazzelli M, Sandercock PA, Chappell FM, et al. Magnetic resonance imaging versus computed tomography for detection of acute vascular lesions in patients presenting with stroke symptoms. Cochrane Database Syst Rev 2009; :CD007424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/56\">",
"      Ay H, Buonanno FS, Rordorf G, et al. Normal diffusion-weighted MRI during stroke-like deficits. Neurology 1999; 52:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/57\">",
"      Sylaja PN, Coutts SB, Krol A, et al. When to expect negative diffusion-weighted images in stroke and transient ischemic attack. Stroke 2008; 39:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/58\">",
"      Kuhl CK, Textor J, Gieseke J, et al. Acute and subacute ischemic stroke at high-field-strength (3.0-T) diffusion-weighted MR imaging: intraindividual comparative study. Radiology 2005; 234:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/59\">",
"      Rosso C, Drier A, Lacroix D, et al. Diffusion-weighted MRI in acute stroke within the first 6 hours: 1.5 or 3.0 Tesla? Neurology 2010; 74:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/60\">",
"      Hunsche S, Moseley ME, Stoeter P, Hedehus M. Diffusion-tensor MR imaging at 1.5 and 3.0 T: initial observations. Radiology 2001; 221:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/61\">",
"      Schellinger PD, Bryan RN, Caplan LR, et al. Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 75:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/62\">",
"      Schulz UG, Briley D, Meagher T, et al. Diffusion-weighted MRI in 300 patients presenting late with subacute transient ischemic attack or minor stroke. Stroke 2004; 35:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/63\">",
"      Kang DW, Latour LL, Chalela JA, et al. Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol 2003; 54:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/64\">",
"      Wen HM, Lam WW, Rainer T, et al. Multiple acute cerebral infarcts on diffusion-weighted imaging and risk of recurrent stroke. Neurology 2004; 63:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/65\">",
"      Coutts SB, Hill MD, Simon JE, et al. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology 2005; 65:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/66\">",
"      Sylaja PN, Coutts SB, Subramaniam S, et al. Acute ischemic lesions of varying ages predict risk of ischemic events in stroke/TIA patients. Neurology 2007; 68:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/67\">",
"      Chalela JA, Alsop DC, Gonzalez-Atavales JB, et al. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000; 31:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/68\">",
"      Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/69\">",
"      Sobesky J, Zaro Weber O, Lehnhardt FG, et al. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 2005; 36:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/70\">",
"      Kranz PG, Eastwood JD. Does diffusion-weighted imaging represent the ischemic core? An evidence-based systematic review. AJNR Am J Neuroradiol 2009; 30:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/71\">",
"      Labeyrie MA, Turc G, Hess A, et al. Diffusion lesion reversal after thrombolysis: a MR correlate of early neurological improvement. Stroke 2012; 43:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/72\">",
"      Ogata T, Nagakane Y, Christensen S, et al. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. Stroke 2011; 42:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/73\">",
"      Ma H, Zavala JA, Teoh H, et al. Fragmentation of the classical magnetic resonance mismatch \"penumbral\" pattern with time. Stroke 2009; 40:3752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/74\">",
"      Olivot JM, Mlynash M, Thijs VN, et al. Geography, structure, and evolution of diffusion and perfusion lesions in Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE). Stroke 2009; 40:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/75\">",
"      Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003; 34:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/76\">",
"      Hjort N, Butcher K, Davis SM, et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005; 36:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/77\">",
"      Neumann-Haefelin T, Wittsack HJ, Wenserski F, et al. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke 1999; 30:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/78\">",
"      Sorensen AG, Copen WA, Ostergaard L, et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiology 1999; 210:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/79\">",
"      Rordorf G, Koroshetz WJ, Copen WA, et al. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI. Stroke 1998; 29:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/80\">",
"      Beaulieu C, de Crespigny A, Tong DC, et al. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol 1999; 46:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/81\">",
"      L&ouml;vblad KO. Diffusion-weighted MRI: back to the future. Stroke 2002; 33:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/82\">",
"      Chalela JA, Kang DW, Luby M, et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol 2004; 55:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/83\">",
"      Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/84\">",
"      Schellinger PD, Thomalla G, Fiehler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007; 38:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/85\">",
"      Bykowski JL, Latour LL, Warach S. More accurate identification of reversible ischemic injury in human stroke by cerebrospinal fluid suppressed diffusion-weighted imaging. Stroke 2004; 35:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/86\">",
"      Lee LJ, Kidwell CS, Alger J, et al. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 2000; 31:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/87\">",
"      Pedraza S, Silva Y, Mendez J, et al. Comparison of preperfusion and postperfusion magnetic resonance angiography in acute stroke. Stroke 2004; 35:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/88\">",
"      Flacke S, Urbach H, Keller E, et al. Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: clinical importance and comparison with hyperdense MCA sign at CT. Radiology 2000; 215:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/89\">",
"      Rovira A, Orellana P, Alvarez-Sab&iacute;n J, et al. Hyperacute ischemic stroke: middle cerebral artery susceptibility sign at echo-planar gradient-echo MR imaging. Radiology 2004; 232:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/90\">",
"      Greer DM, Koroshetz WJ, Cullen S, et al. Magnetic resonance imaging improves detection of intracerebral hemorrhage over computed tomography after intra-arterial thrombolysis. Stroke 2004; 35:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/91\">",
"      Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005; 36:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/92\">",
"      Schramm P, Schellinger PD, Klotz E, et al. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. Stroke 2004; 35:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/93\">",
"      Grolimund P, Seiler RW, Aaslid R, et al. Evaluation of cerebrovascular disease by combined extracranial and transcranial Doppler sonography. Experience in 1,039 patients. Stroke 1987; 18:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/94\">",
"      Camerlingo M, Casto L, Censori B, et al. Transcranial Doppler in acute ischemic stroke of the middle cerebral artery territories. Acta Neurol Scand 1993; 88:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/95\">",
"      Iannuzzi A, Wilcosky T, Mercuri M, et al. Ultrasonographic correlates of carotid atherosclerosis in transient ischemic attack and stroke. Stroke 1995; 26:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/96\">",
"      Razumovsky AY, Gillard JH, Bryan RN, et al. TCD, MRA and MRI in acute cerebral ischemia. Acta Neurol Scand 1999; 99:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/97\">",
"      Alexandrov AV, Demchuk AM, Wein TH, Grotta JC. Yield of transcranial Doppler in acute cerebral ischemia. Stroke 1999; 30:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/98\">",
"      Gao S, Wong KS, Hansberg T, et al. Microembolic signal predicts recurrent cerebral ischemic events in acute stroke patients with middle cerebral artery stenosis. Stroke 2004; 35:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/99\">",
"      Saqqur M, Shuaib A, Alexandrov AV, et al. Derivation of transcranial Doppler criteria for rescue intra-arterial thrombolysis: multicenter experience from the Interventional Management of Stroke study. Stroke 2005; 36:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/100\">",
"      Chernyshev OY, Garami Z, Calleja S, et al. Yield and accuracy of urgent combined carotid/transcranial ultrasound testing in acute cerebral ischemia. Stroke 2005; 36:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/101\">",
"      Dion JE, Gates PC, Fox AJ, et al. Clinical events following neuroangiography: a prospective study. Stroke 1987; 18:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/102\">",
"      Waugh JR, Sacharias N. Arteriographic complications in the DSA era. Radiology 1992; 182:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/103\">",
"      Heiserman JE, Dean BL, Hodak JA, et al. Neurologic complications of cerebral angiography. AJNR Am J Neuroradiol 1994; 15:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/104\">",
"      Johnston DC, Chapman KM, Goldstein LB. Low rate of complications of cerebral angiography in routine clinical practice. Neurology 2001; 57:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/105\">",
"      Willinsky RA, Taylor SM, TerBrugge K, et al. Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature. Radiology 2003; 227:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/106\">",
"      Kaufmann TJ, Huston J 3rd, Mandrekar JN, et al. Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology 2007; 243:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/107\">",
"      Bendszus M, Koltzenburg M, Burger R, et al. Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study. Lancet 1999; 354:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/108\">",
"      Kato K, Tomura N, Takahashi S, et al. Ischemic lesions related to cerebral angiography: Evaluation by diffusion weighted MR imaging. Neuroradiology 2003; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/109\">",
"      Bendszus M, Koltzenburg M, Bartsch AJ, et al. Heparin and air filters reduce embolic events caused by intra-arterial cerebral angiography: a prospective, randomized trial. Circulation 2004; 110:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/56/17290/abstract/110\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1085 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17290=[""].join("\n");
var outline_f16_56_17290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPUTED TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early signs of infarction on noncontrast CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASPECTS method of assessing ischemic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Utility of ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Utility of CT contrast dye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CT angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - CTA source images",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CT perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MAGNETIC RESONANCE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diffusion-weighted imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical utility of DWI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Perfusion-weighted imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Identifying reversible ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MR angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      High susceptibility sequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CT VERSUS MRI TECHNIQUES IN HYPERACUTE STROKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ULTRASOUND METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Carotid and vertebral duplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Transcranial Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combined duplex and TCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CONVENTIONAL ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1085|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/41/29336\" title=\"diagnostic image 1\">",
"      Acute ischemic stroke on CTA-SI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/21/3415\" title=\"diagnostic image 2\">",
"      Classic DWI-PWI mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/10/26789\" title=\"diagnostic image 3\">",
"      Nonclassic DWI-PWI mismatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1085|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/0/12294\" title=\"figure 1\">",
"      ASPECTS study form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/41/10903\" title=\"figure 2\">",
"      Aspects MCA variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/33/40477\" title=\"table 1\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_56_17291="Characteristics TEC";
var content_f16_56_17291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of thymic epithelial cells (TEC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Growth factors for TECs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-1, EGF, beta-FGF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secreted products of TECs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical TEC: IL-1, IL-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary and subcapsular TEC (also called \"giant\" or \"nurse\" cells): IL-1, IL-6, IL-8, G-CSF, M-CSF, TGF-beta, alpha and beta thymosins, thymulin, neuropeptides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adhesion molecules expressed by TECs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LFA-3 (CD58), ligand CD2; ICAM-1 (CD54), ligand LFA-1 (CD11a/CD18)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: colony stimulating factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; G: granulocyte; ICAM: intercellular adhesion molecule; IL: interleukin; LFA: leukocyte function antigen; M: monocyte; TGF: transforming growth factor.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bodey, B, Jr., Siegel, SE, Kaiser, HE. Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. In Vivo 1999; 13:267. and Hadden, JW. Thymic endocrinology. Ann N Y Acad 1998; 840:352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17291=[""].join("\n");
var outline_f16_56_17291=null;
var title_f16_56_17292="Differential diagnosis clinical hyperandrogenism";
var content_f16_56_17292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of clinical hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Frequency (percent)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Age of onset years",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Time of onset to presentation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Menstrual disturbance",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Virilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCOS and related disorders",
"       </td>",
"       <td>",
"        &gt;95",
"       </td>",
"       <td>",
"        15 to 25",
"       </td>",
"       <td>",
"        Years",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CAH",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        Congenital",
"       </td>",
"       <td>",
"        Birth/adolescence/adulthood",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal tumor",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        Any time",
"       </td>",
"       <td>",
"        Weeks-months",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian tumor",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        Any time",
"       </td>",
"       <td>",
"        Weeks-months",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing's syndrome",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        Any time",
"       </td>",
"       <td>",
"        Months-years",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthecosis ovary",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        Pre- to post-menopause",
"       </td>",
"       <td>",
"        Months-years",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCOS: polycystic ovary syndrome; CAH: congenital adrenal hyperplasia; (+): present; (-): absent; (+/-): present or absent.",
"    </div>",
"    <div class=\"reference\">",
"     From: Dennedy MC, Smith D, O'Shea D, McKenna TJ. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol 2010; 162:213. Copyright &copy; Society of the European Journal of Endocrinology 2010. Reproduced by permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17292=[""].join("\n");
var outline_f16_56_17292=null;
var title_f16_56_17293="Fertility preservation for women treated w gonadotoxic therapies";
var content_f16_56_17293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fertility preservation options for women treated with gonadotoxic therapies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Investigational",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Cryopreservation of embryos for future implantation",
"       </td>",
"       <td>",
"        Typically requires ovarian stimulation, which takes 10 to 14 days from the beginning of a menstrual cycle. Oocytes are harvested under ultrasound guidance and fertilized in vitro.",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         Requires sperm from the woman's partner. If no partner, then donor sperm can be used.",
"        </p>",
"        <p>",
"         Induction of high estrogen levels during ovarian stimulation is a concern in women with estrogen-responsive malignancies. Aromatase inhibitors can be used to minimize estrogen exposure.",
"        </p>",
"        Costly. Approximately $8000 to 12,000 per cycle, $500 to 1000/year storage fees.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Oocyte cryopreservation (mature oocytes)",
"       </td>",
"       <td>",
"        Typically requires ovarian stimulation, which takes 10 to 14 days from the beginning of a menstrual cycle. Oocytes are harvested under ultrasound guidance and frozen without being fertilized.",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         Induction of high estrogen levels during ovarian stimulation is a concern in women with estrogen-responsive malignancies. Aromatase inhibitors can be used to minimize estrogen exposure.",
"        </p>",
"        Costly. Approximately $8000 to 12,000 per cycle, $500 to 1000/year storage fees.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Oocyte cryopreservation (immature oocytes)",
"       </td>",
"       <td>",
"        Does not require ovarian stimulation. Germinal oocytes are harvested under ultrasound guidance and frozen without being fertilized.",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Only a few pregnancies have been reported.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Ovarian cryopreservation and transplantation",
"       </td>",
"       <td>",
"        Outpatient surgical procedure to obtain strips of ovarian tissue, which are frozen and reimplanted when pregnancy is desired.",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Ovarian transplantation is not recommended in women at increased risk of developing ovarian cancer.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Gonadal shielding during radiation therapy",
"       </td>",
"       <td>",
"        Shielding gonads during radiation therapy reduces gonadal exposure to scatter radiation.",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         Not possible if gonads are in the radiation field.",
"        </p>",
"        Requires expertise to properly place shields.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Ovarian transposition (oophoropexy)",
"       </td>",
"       <td>",
"        <p>",
"         Outpatient surgical procedure to reposition the ovaries away from the radiation field.",
"        </p>",
"        Should be performed just before radiation therapy to minimize chance that ovaries will return to their former position.",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         Approximately 50 percent chance of success.",
"        </p>",
"        Ovaries may need to be repositioned to allow assisted or natural conception.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Trachelectomy",
"       </td>",
"       <td>",
"        Inpatient surgical procedure to remove the cervix while preserving the uterus.",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         Only useful for women with early stage cervical cancer.",
"        </p>",
"        <p>",
"         Prior to attempting pregnancy following trachelectomy, the patient may require an abdominal cerclage.",
"        </p>",
"        Pregnancy following abdominal cerclage may be complicated due to the difficulty in differentiating preterm labor from preterm contractions, the risk of uterine rupture, and the need for cesarean delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian suppression with gonadotropin releasing hormone (GnRH) analogs or antagonists",
"       </td>",
"       <td>",
"        Administer before and concurrent with chemotherapy to protect ovarian tissue.",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        <p>",
"         True efficacy unknown. No randomized trial has shown benefit to fertility.",
"        </p>",
"        <p>",
"         Side effects include hot flashes and vaginal atrophy. Suppression of menses is a benefit in women at risk of menorrhagia from thrombocytopenia.",
"        </p>",
"        Approximately $500/month.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lee SJ, Schover LR, Patridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17293=[""].join("\n");
var outline_f16_56_17293=null;
var title_f16_56_17294="Contents: Substance use disorders";
var content_f16_56_17294=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Substance use disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Substance use disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alcohol abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/22/2409\">",
"           Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4361\">",
"           Ambulatory alcohol detoxification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/17/42265\">",
"           Brief intervention for unhealthy alcohol and other drug use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/13/15577\">",
"           Identification and management of alcohol use disorders in the perioperative period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/8/17544\">",
"           Nutritional status in alcohol dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/48/19209\">",
"           Pharmacotherapy for alcohol abuse and dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41847\">",
"           Psychosocial treatment of alcohol abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-specific abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32970\">",
"           Cocaine abuse and dependence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22920\">",
"           Methamphetamine abuse and dependence: Epidemiology, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3784\">",
"           Opioid abuse and dependence: Overview and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1191\">",
"           Opioid detoxification during treatment for addiction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27160\">",
"           Prescription drug abuse and addiction: Prevention, identification, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25993\">",
"           Screening for unhealthy use of alcohol and other drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29514\">",
"           Treatment of opioid abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2936\">",
"           Clinical management of substance dependence across the continuum of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41177\">",
"           Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36521\">",
"           Dual diagnosis: Severe mental illness and substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5562\">",
"           Impaired healthcare provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2313\">",
"           Motivational interviewing for substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/19/9529\">",
"           Non-hormonal performance enhancement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36535\">",
"           Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5033\">",
"           Substance use disorders: Principles for recognition and assessment in general medical care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29993\">",
"           Treatment of co-occurring anxiety disorders and substance use disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8DFE5034BC-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_56_17294=[""].join("\n");
var outline_f16_56_17294=null;
var title_f16_56_17295="Pseudoalveolar sarcoidosis CT";
var content_f16_56_17295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, ill-defined left perihilar consolidation, unilateral left hilar enlargement, and bilateral peripheral poorly defined nodules are present. These findings are suggestive of the pseudoalveolar form of sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_56_17295=[""].join("\n");
var outline_f16_56_17295=null;
